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Alzheimer’s disease (AD), the single most common cause of dementia, is characterized by massive 
neuronal damage leading to cerebral atrophy and the loss of cognitive function. Most AD cases 
(˃95%) are sporadic. Sporadic AD is a highly complex disease for which neither the causal 
agent(s) nor the molecular mechanisms behind are well known. Among the environmental risk 
factors, persistent brain infections, particularly those induced by Herpes simplex virus type 1 
(HSV-1), seem to play a key role in AD pathogenesis. Another factor is oxidative stress (OS), 
intimately linked to aging and, therefore, thought to be crucial to the onset and development of the 
disease. Our group works with both factors to simulate the sporadic form of AD in vitro. The 
objective of the present study was the identification of genes and pathways associated with AD to 
provide novel diagnostic tools predicting the risk and/or the progression of the symptoms, and to 
establish possible therapeutic targets for the disease. Gene expression studies of the human 
neuroblastoma cell line SK-N-MC have identified a set of OS-regulated genes in infected cells and 
in cells harbouring APP with the Swedish mutation (APPswe), a cell model of familial AD. Analysis 
of these genes revealed that the main pathway altered was the lysosomal system suggesting that the 
interaction of OS with both HSV-1 and APPswe affects lysosomal function. These data support 
earlier findings and those of other authors highlighting the role of lysosomal pathway in early 
stages of AD neurodegeneration. To strengthen this hypothesis, we focused on the lysosomal 
pathway in our cell models and found that HSV-1 infection and OS led to an increase of lysosomal 
content, decreased activity of several lysosomal hydrolases, inhibition of the endocytosis-mediated 
degradation of the EGF receptor, and accumulation of intracellular cholesterol. Taken together, 
these results confirm that the lysosomal pathway is severely impaired. The lysosomal-associated 
membrane protein 2 (LAMP2) gene was one of the most strongly modulated ones in the differential 
expression analysis. In addition, LAMP2 has been functionally involved in the export of 
cholesterol out of lysosomes and in the final stages of autophagy. Both processes are essential for 
lysosome function and have been reported to be deeply altered in AD. All these evidences point to 
LAMP2 as a strong candidate to mediate the lysosomal alterations observed in our models. Indeed, 
the case/control studies revealed LAMP2 genetic variants to be associated with AD risk suggesting 
that LAMP2 is involved in the disease. To study the role of this candidate in the neurodegenerative 
events induced by HSV-1, human neuroblastoma cell lines with a stable knockdown for LAMP2 
were generated in-house and two additional murine LAMP2-deficient cell lines—MEFs and N2a—
were used. LAMP2 deficiency induced a less effective HSV-1 infection in both cell lines 
suggesting a functional role of LAMP2 in viral cycle. Preliminary results indicate that the absence 
of LAMP2 does not affect HSV-1-induced neurodegenerative events like tau phosphorylation, 
accumulation of intracellular Aβ42 and inhibition of Aβ secretion. In conclusion, the results of the 
current project point to alterations in the lysosomal pathway as a potential common pathogenic 
mechanism underlying the different forms of AD (familial and sporadic) and suggest that 
pharmacological modulation of this pathway might be beneficial for AD. 
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La enfermedad de Alzheimer (EA) es la causa más común de demencia y se caracteriza por un 
masivo daño neuronal que conduce a la atrofia cerebral y a la pérdida de funciones cognitivas. En 
la gran mayoría de los casos (˃95%), la EA constituye una enfermedad compleja cuya causa y 
mecanismos moleculares aún se desconocen. Entre los factores de riesgo ambientales, las 
infecciones cerebrales, y en particular la infección por el virus herpes simplex 1 (HSV-1), 
desempeñan un papel clave en la patogénesis. Otro factor clave en el desarrollo de la enfermedad 
es el estrés oxidativo (EO) asociado al envejecimiento. Nuestro grupo trabaja con ambos factores 
para simular la forma esporádica de la EA in vitro. El objetivo del presente estudio fue la 
identificación de genes y rutas asociados a la EA que pudiesen integrarse en procedimientos 
diagnósticos útiles para evaluar el riesgo o el curso clínico probable de la enfermedad, o constituir 
dianas terapéuticas potenciales. Mediante estudios de expresión génica en la línea celular de 
neuroblastoma humano SK-N-MC, hemos identificado un conjunto de genes cuya expresión se 
regula por EO tanto en células infectadas como en células portadoras de la mutación APPswe, un 
modelo celular de la EA familiar. El análisis de los genes modulados reveló que el sistema 
lisosomal es la principal ruta alterada sugiriendo que la interacción del EO con HSV-1 y con la 
mutación APPswe modifica la función lisosomal, y apoya datos de otros autores sobre la implicación 
de esta vía en las primeras etapas de la neurodegeneración. Para confirmar la hipótesis, hemos 
analizado la vía lisosomal demostrando que el HSV-1 y el EO producen un aumento en la cantidad 
de lisosomas, una inhibición de la actividad de varias hidrolasas lisosomales y de la degradación 
del receptor de EGF mediada por endocitosis, y una acumulación intracelular de colesterol. En 
conjunto, estos resultados indican que la funcionalidad de la vía lisosomal está afectada. El gen 
lisosomal LAMP2 fue uno de los más modulados en el análisis de expresión diferencial. Además, 
LAMP2 está implicado en las etapas finales de la autofagia y en el transporte de colesterol fuera 
del compartimento lisosomal. Ambos procesos son esenciales para la función lisosomal y están 
fuertemente alterados en la EA. Todas estas evidencias apuntan a LAMP2 como un posible 
candidato para mediar las alteraciones lisosomales de nuestros modelos. Además, los estudios 
caso/control mostraron variantes genéticas de LAMP2 asociadas con riesgo de EA, sugiriendo su 
implicación en la enfermedad. Para estudiar su participación en la neurodegeneración inducida por 
HSV-1, hemos generado varias líneas celulares SK-N-MC con una inhibición estable de la 
expresión de LAMP2. Además, hemos analizado líneas celulares murinas—MEFs y N2a—
deficientes en LAMP2. La ausencia de LAMP2 indujo una inhibición de la infección sugiriendo 
que ejerce un papel funcional en el ciclo viral. Resultados preliminares indican que la ausencia de 
LAMP2 no afecta a los marcadores de neurodegeneración inducidos por HSV-1, como son la 
fosforilación de tau, la acumulación intracelular de Aβ42 y la inhibición de la secreción de Aβ. En 
conclusión, los resultados del presente trabajo apuntan a alteraciones en la función lisosomal como 
posible mecanismo patogénico común de las formas monogénica y esporádica de la EA y sugieren 
que la modulación farmacológica de esta vía podría ser beneficiosa para la enfermedad. 
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TBS ........................................................................................................................ Tris-buffered saline 
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TREM2 ................................................................... Triggering receptor expressed on myeloid cells 2 
V ............................................................................................................................................. Vacuolar 
WT .......................................................................................................................................... Wildtype 
X-XOD ....................................................................................................... Xanthine-xanthine oxidase 
β-ME ................................................................................................................... Beta-mercaptoethanol 
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1. General aspects of Alzheimer’s disease 
Alzheimer’s disease (AD), the most common cause of dementia, is characterized by an 
irreversible progression of neuronal death, memory loss, as well as general cognitive decline. The 
disease is divided into two subtypes based on the genetic background: familial early-onset AD 
(FAD) and sporadic late-onset AD (SAD). 99% of all cases demonstrate the sporadic form:  
a complex interaction of genetic and environmental factors. Among the non-genetic risk factors, 
age is the most important one. AD incidence increases exponentially with ages from 65 to 90 years 
and doubles approximately every 5 years (Jorm et al., 1998). Further, other non-genetic factors for 
AD are female gender (Vina et al., 2010), oxidative stress (Markesbery et al., 1999; Smith et al., 
2000) and lipid alterations (Bjorkhem, 2006; Grimm et al., 2013). Growing evidence points to 
chronic or latent infections of the central nervous system (CNS) as a major player in the 
pathogenesis of AD (Harris et al., 2015; Itzhaki et al., 2016).  
In 1906, Alois Alzheimer described for the first time the neuropathological lesions he 
observed in a brain autopsy of a patient with early-onset dementia, which are considered until today 
the two pathological hallmarks of AD. He observed the presence of “striking changes in 
neurofibrils” and the distribution of “minute military foci caused by the deposition of a special 
substance”. Today, these features are known as neurofibrillary tangles (NFTs) and senile plaques 
(SPs), respectively. SPs are extracellular aggregates of β-amyloid peptide (Aβ), a proteolytic 
product of the amyloid precursor protein (APP). NFTs are intracellular and are composed mainly 
by hyperphosphorylated microtubule-associated protein tau (MAPT).  
The human APP gene was first identified in 1987 (Kang et al., 1987) and belongs, together 
with the APP-like protein 1 (APLP1) and 2 (APLP2), to the APP protein family in mammals. All 
three are type I transmembrane proteins with a single membrane-spinning domain, a large 
extracellular N-terminal region and a short cytoplasmic C-terminal tail (De Strooper et al., 2000). 
Although they undergo similar processing, only APP contains the sequence encoding the Aβ 
domain. APP is localized on chromosome 21 and alternative splicing of exons 7 and 8 gives rise to 
three major isoforms: APP695, APP751 and APP770 (containing 695, 751, and 770 amino acids, 
respectively) (Kitaguchi et al., 1988). APP751 and APP770 are ubiquitously expressed (Schmechel 
et al., 1988), whereas APP695 is predominantly expressed in neurons (Tanaka et al., 1988). 
A role of APP in transmembrane transduction, cell adhesion, calcium metabolism, neurite 
outgrowth, and synaptogenesis has been reported (Muller et al., 2017). APP is localized on the 
plasma membrane, but also in membranes of the endoplasmic reticulum (ER), Golgi, trans-Golgi-
network (TGN), lysosomes, endosomes, and mitochondria (Zhang et al., 2011).  
APP is mainly processed in the canonical pathway, which includes the amyloidogenic and 
non-amyloidogenic route (Figure 1) (Zhang et al., 2011). The latter is more prevalent and excludes 
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the generation of Aβ. Here, APP is first cleaved by the α-secretase within the Aβ-domain, which 
results in a large N-terminal ectodomain (sAPPα) and the membrane-remaining C-terminal 
fragment (α-CTF), which is subsequently cleaved by the γ-secretase. This second cleavage 
produces the short peptide P3 and the APP intracellular domain fragment (AICD or γ-CTF). In 
contrast, the amyloidogenic pathway leads to the production of Aβ because of the sequential 
cleavage of the β- and γ-secretase. In a first step, the β-secretase cleaves APP in the N-terminal end 
of the Aβ domain to generate sAPPβ and the 99 amino acid long membrane-bound C-terminal 
fragment (β-CTF). Further processing of β-CTF causes Aβ and γ-CTF-formation. This final step 
can produce Aβ peptides of different length, between 39 and 42 amino acids. The non-canonical 
processing routes have been described more recently and new secretases and corresponding 
proteolytic fragments have been identified, with probably more to be discovered (Muller et al., 
2017).  
?
??????????????????????????????????????????????????????????????
? ???? ??????????????????????????????????
The generation of Aβ takes place in different cellular organelles including plasma 
membrane, ER, Golgi/TGN, lysosomes, and endosomes. The Aβ40 isoform is the most abundant 
(80-90%), whereas Aβ42 is more hydrophobic and fibrillogenic (LaFerla et al., 2007). Aβ peptides 
not only differ in length, additional heterogeneity is added by modifications through 
aminopeptidases, glutaminylcyclases, and other modifications that might contribute to Aβ 
neurotoxicity (De Strooper, 2010). Monomeric Aβ peptides form low molecular oligomers 
(dimer/trimer) and then soluble high molecular aggregates. Those finally build spherical oligomers 
composed of 12-24 monomers, which prolong to form protofibrils and become insoluble fibrils 
(Glabe, 2008).  
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The amyloid hypothesis, which has been the predominant framework for AD research, 
postulates that the accumulation of Aβ acts as the root cause of AD and initiates its pathogenesis 
(Selkoe et al., 2016). For a long time, it has been believed that insoluble extracellular fibrils 
(classical amyloid plaques) were the most neurotoxic. However, they are also present in the brain 
of non-demented individuals and do not correlate with deterioration of cognitive function 
(Aizenstein et al., 2008). Clinical trials that removed plaques failed to reverse the damage or stop 
disease progression (Cappai et al., 2008; Hardy, 2009). Focus switched then to soluble Aβ 
aggregates as the primary toxic species. Indeed, those are better correlated with disease severity 
(Tomic et al., 2009). How exactly Aβ oligomers mediate neurotoxicity is still unknown. Several 
studies propose the interaction of soluble extracellular Aβ with receptors of the cell surface as 
causative for neuronal dysfunction and neurodegeneration. Aβ oligomers caused functional 
disruption of the N-methyl-D-aspartate (NMDA) receptor by inducing its endocytosis and 
repressing NMDA-evoked currents in neurons (Snyder et al., 2005). Interaction of Aβ with nerve 
growth factor receptor induces neuronal death (Yamamoto et al., 2007) through the p75 
neurothrophin receptor—a member of the tumor necrosis factor receptor superfamily 
(Sotthibundhu et al., 2008). Another mechanism by which Aβ might induce neurodegeneration is 
the ability of this peptide to integrate into membranes to form membrane channels. These channels 
permit influx of some ions—including calcium—leading to the disruption of calcium homeostasis 
(Kawahara et al., 2000), increased reactive oxygen species (ROS) formation (Yatin et al., 1998) 
and tau phosphorylation (Takashima et al., 1993). In contrast, others say that amyloid oligomers 
cause membrane permeabilization by affecting the lipid bilayer conductance (Kayed et al., 2004).  
Numerous authors suggest that intracellular accumulation of Aβ is an even earlier event 
preceding the formation of extracellular deposits of Aβ (LaFerla et al., 2007). In this sense, 
intracellular Aβ may contribute to AD pathology through the inhibition of mitochondrial enzymes 
causing a reduction in oxygen consumption (Caspersen et al., 2005), as well as mediating the 
inhibition of proteasome function (Almeida et al., 2006). Furthermore, intraneuronal Aβ peptides 
cause synaptic dysfunction and memory impairment (Billings et al., 2005; Oddo et al., 2003). Other 
studies report Aβ toxicity trough the inhibition of cell redox activity (Shearman et al., 1994), 
induction of apoptosis and activation of caspases (Lustbader et al., 2004), as well as the possible 
contribution to tau phosphorylation and paired helical filament (PHF) formation (Lewis et al., 
2001; Zheng et al., 2002). 
The second neuropathologic hallmark of AD are NFTs, composed of abnormally 
hyperphosphorylated tau (p-tau) proteins that aggregate into PHFs. Tau belongs to a family of 
phosphoproteins—the so-called microtubule-associated proteins (MAPs). Tau and two other 
proteins—MAP1 and MAP2—are the major MAPs expressed in mature neurons. For long, the only 
known functions were the promotion of the assembly of tubulin into microtubules and the 
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stabilisation of their structure (Weingarten et al., 1975). However, tau has been proposed to be a 
key regulator of axonal transport and signalling cascades, cellular responses to heat shock, and 
adult neurogenesis (Morris et al., 2011). Tau function is mainly regulated by the degree of 
phosphorylation, however tau can also receive many other posttranslational modifications, such as 
glycosylation, ubiquitination, glycation, nitration and truncation (Avila et al., 2004). The human tau 
gene (MAPT) is localized on chromosome 17 and contains 16 exons. Alternative splicing of exon 2, 
3, and 10 generates six different isoforms ranging from 48 to 68 kDa in molecular weight.  
Tau contains 85 putative phosphorylation sites (Goedert et al., 1989) that can be 
phosphorylated by several kinases. Among them, the cyclin-dependent protein kinase 5 (CDK5), 
glycogen synthase kinase 3 (GSK3), protein kinase A (PKA), calcium and calmodulin-dependent 
protein kinase II (CaMKII), mitogen activated protein kinase ERK 1/2, and stress-activated protein 
kinases have mostly been implicated in the hyperphosphorylation of tau. The contrary event—
dephosphorylation—is managed by the activity of phosphoseryl/phosphothreonyl protein 
phosphatases (PP). PP2A is the major enzyme involved in dephosphorylation of tau in the brain 
(Gong et al., 2000).  
In AD, 40 phosphorylation sites have been reported (Hanger et al., 2009; Wang et al., 
2008) including mainly serine/threonine residues and only two tyrosine residues. P-tau might result 
from upregulation of tau kinases and/or downregulation of phosphatases (Buee et al., 2000; 
Trojanowski et al., 1995). Indeed, PP2A activity is reduced in selected areas of AD brains 
(Vogelsberg-Ragaglia et al., 2001). All six tau isoforms are abnormally hyperphosphorylated and 
aggregate into PHFs leading to NFTs, neuropil threads, and plaque dystrophic neurites in the brain 
of AD cases (Grundke-Iqbal et al., 1986; Iqbal et al., 2009). In contrast to SPs, the density of NFTs 
has been correlated with disease progression (Arriagada et al., 1992; Giannakopoulos et al., 2003). 
Neurofibrillary degeneration has been observed not only in brains of AD patients, but also in a 
group of several other neurodegenerative diseases, called tauopaties. This group of diseases include 
frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), progressive 
supranuclear palsy and corticobasal dementia.  
The phosphorylation level of tau affects the interaction of tau with microtubules and other 
proteins, and its tendency to form aggregates. In AD, p-tau loses its affinity to microtubules and 
leads to the formation of NFTs (Avila, 2000). P-tau sequesters normal tau (Alonso et al., 1996; 
Alonso et al., 1994), MAP1 and MAP2, thereby further enhancing its toxic effects (Alonso et al., 
1997). Such breakdown of the microtubule network might affect other subcellular structures such 
as mitochondria or lysosomes, and further promote tau pathology.  
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2. Risk factors for AD 
2.1. Genetic predisposition 
Genetic researchers first could identify the 3 genes associated with FAD: APP, Presenilin 1 
(PSEN1) and Presenilin 2 (PSEN2). Mutations and duplications of these genes cause autosomal-
dominant FAD with a penetrance of almost a 100%. PSEN1 is the most commonly involved gene, 
with 221 pathogenic mutations reported in the Alzforum database (www.alzforum.org/mutations). 
Those account for about 80% autosomal dominant FAD cases, mutations in APP for about 15% 
and PSEN2 for 5%. What all these mutations have in common is that they increase the aggregation 
of the Aβ peptide by increased production or production of a more aggregation-prone form of the 
peptide (Rogaeva, 2002). Although these genes are known to cause FAD, there are additional 
variants in APP, PSEN1, PSEN2 and ADAM10—the major ɑ-secretase involved in proteolysis of 
the APP ectodomain—that alter the risk in SAD cases (Cruchaga et al., 2012). 
After the discovery of APP, PSEN1 and PSEN2, genetic studies aimed to identify genes 
causing the more frequent late-onset form of the disease. In this way, already twenty-five years 
ago, Apolipoprotein E (APOE) was discovered as a genetic risk factor for SAD (Corder et al., 
1993). The APOE gene is located at chromosome 19q13.2 and encodes a highly pleiotropic 
glycoprotein (Siest et al., 1995). There are three alleles (ε2, ε3, and ε4) for the APOE gene, and risk 
of AD and early age of onset is associated with APOE-ε4, whereas the ε2 allele is associated with 
protection and delayed age of onset (Corder et al., 1994). Still, the combinations of these four genes 
(APP, PSEN1, PSEN2 and APOE) might explain 30-50% of inheritability. Advances in genomic 
technologies and the advent of genome-wide association studies (GWAS) have allowed the 
identification of novel genetic associations. Consortia like the Genetic and Environmental Risk in 
Alzheimer’s Disease (GERAD) and the European Alzheimer’s Disease Initiative (EADI) were able 
to identify genome-wide significant associations with single nucleotide polymorphisms (SNPs) in 
more than twenty loci besides APOE (Lambert et al., 2009; Lambert et al., 2013; Lambert et al., 
2011). However, most of these loci present common variants with a small individual effect on risk 
(Figure 2), but still have helped create a broader picture of the processes and pathways involved. It 
has been estimated that they only modify disease risk by 0.10 to 0.15-fold, whereas the presence of 
APOE-ε4 results in an almost 4-fold increase (Bertram et al., 2010). Interestingly, these variants 
can be clustered into three pathways, namely lipid metabolism, immune response, and endocytosis 
(International Genomics of Alzheimer's Disease, 2015; Karch et al., 2015).  
New approaches are necessary in order to identify new candidates with higher risk. 
Recently, whole-exome sequencing and whole-genome sequencing strategies discovered rare 
coding variants of two AD-linked genes. The variants in the triggering receptor expressed on 
myeloid cells 2 (TREM2) (p.R47H) and phospholipase D3 (PLD3) (V232M) genes appear to confer 
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a higher risk for AD than other genes identified by GWAS (Cruchaga et al., 2014; Guerreiro et al., 
2013). Despite all efforts, we are still under pressure to explain the missing inheritability, which in 
part might be explained by epistasis, rare variants, and somatic mutations (Karch et al., 2015). 
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2.2. Infectious hypothesis and AD 
Growing evidence support that chronic or latent infection of the CNS might be implicated 
in the etiology of AD (Miklossy, 2011). The idea of the so-called pathogen/infectious hypothesis 
came up in the 1960s and has gained support since then. First evidence came from the fact that 
several microbes can access the CNS, remain there in latent form by evading the host immune 
response, and that they are highly prevalent in the AD brain (Harris et al., 2015). Among them, 
bacteria like Chlamydia pneumonia (Gerard et al., 2006), Helicobacter pylori (Kountouras et al., 
2007) and several types of spirochaete (Miklossy, 2011), and herpes viruses such as Epstein Barr 
Virus (EBV), Herpes simplex virus type 1 (HSV-1), Cytomegalovirus (CMV), and Human herpes 
virus 6 (HHV6), have been associated with AD (Harris et al., 2015). Two recent studies reported 
the presence of fungal infections in the brain of AD patients (Alonso et al., 2014; Pisa et al., 2015). 
The hypothesis states that in combination with genetic risk factors, these pathogens participate in 
the generation of the Aβ peptide, tau hyperphosphorylation and inflammation. Of all studied 
pathogens in relation with AD, HSV-1 has emerged as a major factor in the etiology of the disease 
(Itzhaki, 2014). 
2.2.1. HSV-1 and AD 
HSV-1 belongs to the alphaherpesvirus subfamily. Other members of this group are the 
closely related HSV-2 and Varicella zoster virus (Steiner et al., 2007). HSV-1 is a ubiquitous 
neurotropic virus, with a worldwide seroprevalence of more than 80% in adults. The virion of all 
alphaherpesviruses consists of four components: (1) an electron-dense core containing lineal viral 
DNA of approximately 152 kDa, (2) the capsid, an icosadeltahedral structure that surrounds the 
core composed of 6 structural proteins, (3) the surrounding tegument, a protein layer composed of 
22 viral proteins and (4) an envelope (Owen et al., 2015). The envelope is derived from cellular 
membranes and includes viral glycoproteins, which are important for the virus adsorption to the 
cell surface, receptor recognition and membrane fusion to enable viral entry into the host cell 
(Fields et al., 1996).  
HSV-1 usually enters orofacial mucosal epithelia cells where productive infection takes 
place (Figure 3). From there, the virus can spread to neurons of the trigeminal ganglia innervating 
the epithelium where it can establish lifelong latency (Kennedy et al., 2015; Nicoll et al., 2012). 
After primary infection, the virus can replicate or stay latent in the neuron cell body until 
reactivation by diverse stimuli (like stress and immunosuppression). When reactivated, the virus 
travels back to the primary site of infection where it causes the so-called cold sores (herpes 
labialis). Infected peripheral nervous system (PNS) neurons are in direct synaptic contact with CNS 
neurons providing a direct route of spread from the periphery (Koyuncu et al., 2013). Once in the 
CNS, the virus can stay latent until periodical reactivation, which could cause neuronal damage. 
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Acute HSV-1 infection is known to cause different neurological diseases, like herpes keratitis 
(Rowe et al., 2013) or encephalitis (Bradshaw et al., 2016), and mounting evidence links it to AD.  
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Brain autopsies showed that latent HSV-1 is present in a high proportion of SAD and 
normal elderly individuals, and that it was found in the areas most affected by AD, namely 
temporal and frontal cortices and hippocampus (Jamieson et al., 1991). Furthermore, the viral DNA 
seems to colocalize with SPs suggesting an active role of the virus in their generation (Wozniak et 
al., 2009). In contrast, no viral DNA has been found in younger brains (Wozniak et al., 2005), 
suggesting that HSV-1 reaches the CNS at older age when the immune system declines. Evidence 
from epidemiological studies postulate that in synergy with the possession of the APOE-ε4 allele, 
HSV-1 infection represents a risk factor for AD (Itzhaki et al., 1997), even though neither of the 
two factors alone is necessary nor sufficient for the development of the disease. In this sense, using 
mice models, our group previously showed that the ApoE dose and genotype determine the viral 
load in the CNS. The viral neuroinvasion was reduced in animals lacking the ApoE gene compared 
to wildtype animals and a direct correlation between HSV-1 concentration and ApoE allelic dose 
was detected (Burgos et al., 2002). In posterior reports, we then showed that during both acute and 
latent infection, ApoE-ε4 was more efficient than ApoE-ε3 in promoting viral colonisation of the 
brain (Burgos et al., 2003; Burgos et al., 2006). Besides APOE, many genes are thought to interact 
with some aspect of HSV-1 infection. Indeed, GWAS identified a set of genes associated with SAD 
which may affect the individual susceptibility to HSV-1 infection (Porcellini et al., 2010).  
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These genes could constitute in a genetic fingerprint modulating the individual’s susceptibility to 
HSV-1 infection thereby causing neuronal loss, inflammation and Aβ deposition (Licastro et al., 
2011; Porcellini et al., 2010). Letenneur and colleagues studied the presence of HSV IgG (a marker 
of primary infection) and IgM antibodies (a marker of HSV reactivation) in the serum of AD 
patients and controls. They found out that the reactivation of HSV is highly correlated with the 
progression of the disease (Letenneur et al., 2008). These results were recently confirmed by 
Lövheim’s group in an independent study (Lovheim et al., 2014). Finally, several researchers, 
including our group, linked HSV-1 to the main neuropathological hallmarks of AD in neuronal and 
animal models of HSV-1 infection: infection leads to an accumulation of intracellular Aβ (Santana 
et al., 2012; Wozniak et al., 2007), autophagic vesicles (Itzhaki et al., 2008; Santana et al., 2012) 
and hyperphosphorylated tau protein (Alvarez et al., 2012; Wozniak et al., 2009).  
Under these circumstances it is not surprising that researchers study the effect of anti-viral 
treatments in relation with AD (Itzhaki et al., 2012). In cell culture experiments, the use of 
acyclovir (ACV), an inhibitor of viral replication, reduced the amount of HSV-1, Aβ formation and 
tau hyperphosphorylation (Wozniak et al., 2011). Valacyclovir, the ACV’s biodrug, is already 
being tested in clinical trials for its use in multiple sclerosis with promising results (Friedman et al., 
2005), although it has not been tested in AD patients so far. These preliminary results indicate that 
antiviral treatment might stop or slow down the disease progression especially in AD patients who 
are APOE-ε4 carriers. In this context, a large group of researchers and clinicians gathered together 
recently to express their concern about the fact that—despite all evidence—the infectious 
hypothesis still is not fully accepted and no effort is made to initiate antiviral/antimicrobial clinical 
studies in relation to AD (Itzhaki et al., 2016). 
2.2.2. Interaction between HSV-1 and oxidative stress 
Oxidative stress contributes to neuronal damage and has been associated with neuronal cell 
death in certain neurodegenerative diseases such as AD (Andersen, 2004; Nunomura et al., 2006). 
Although the most important non-genetic risk factor for AD is aging, various studies report the 
presence of oxidative stress in the brains and peripheral tissues of patients with AD and animal 
models (Gibson et al., 2005). Oxidative stress results from an imbalance in prooxidant/antioxidant 
homeostasis leading to the generation of toxic ROS. Under normal conditions, ROS are produced 
as a consequence of cellular processes and their amount is controlled by antioxidants such as 
glutathione peroxidase and catalase and by non-enzymatic antioxidant molecules such as 
glutathione, vitamin E, ascorbic acid and carotenoids (Su et al., 2008). In relation with AD, an 
increase of OS markers, including RNA/DNA damage and lipid peroxidation, have been reported 
in AD brains and animal models of the disease (Gabbita et al., 1998; Nunomura et al., 1999; 
Williams et al., 2006). Several studies reported increased activity of the major antioxidant enzymes 
in cortex and hippocampus of AD patients (Pappolla et al., 1992; Zemlan et al., 1989). 
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The high oxygen consumption of the human brain makes this organ especially susceptible 
to oxidative stress (Shulman et al., 2004). Since aging is associated with increased ROS production 
and decreased ROS clearance, in age-related neurodegenerative diseases—like AD—oxidative 
stress is not only an early event but also would play an important role in initiating the disease 
through activation of cell signalling pathways leading to apoptosis and neuroinflammation (Cai et 
al., 2011). On the other hand, oxidative stress contributes to Aβ generation and NFTs by different 
mechanisms (reviewed in Cai et al., 2011).  
Our group has also found several evidence linking OS to alterations characteristic of AD. 
Using the free radical-generating system xanthine-xanthine oxidase (X-XOD) to induce mild 
oxidative stress in neuronal cell models, as it might occur during normal aging, we showed that OS 
alters cholesterol biosynthesis—one of the earliest events observed in AD patients (Recuero et al., 
2009). We then reported that the X-XOD system is able to modify the metabolism/processing of 
APP (Recuero et al., 2010) through the autophagy-lysosome and ubiquitin-proteasome pathway 
(Recuero et al., 2013). In combination with HSV-1, we showed that OS enhances the intracellular 
accumulation of Aβ mediated by HSV-1 infection, and further decreased its secretion to the 
extracellular medium. Furthermore, OS potentiates the accumulation of immature autophagic 
compartments and the inhibition of the autophagic flux induced by HSV-1. At the same time, OS 
reduced the efficiency of HSV-1 infection (Santana et al., 2013).  
Other authors also reported association between acute and latent HSV-1 infection of the 
CNS and oxidative damage (Milatovic et al., 2002; Valyi-Nagy et al., 2000). HSV-1 has been 
described to induce the peroxidation of lipids (Palu et al., 1994). During acute infection, HSV-1 
provokes encephalitis in mice accompanied by severe inflammation and elevated levels of  
F2-isoprostanes and F4-neuroprostanes—two markers of oxidative damage (Milatovic et al., 2002). 
Latent HSV-1 infection induces oxidative damage of RNA and DNA molecules in infected areas of 
the murine brain (Valyi-Nagy et al., 2000). On the other hand, latent infection of HSV-1 in murine 
models is also associated with persistent and chronic inflammation in the brain, and with high 
levels of proinflammatory cytokines such as the tumor necrosis factor α (TNFα) and increased 
activity of induced nitric oxide synthase (iNOS). These factors may play an important role in 
preventing the reactivation of HSV-1 (Koprowski et al., 1993; Marques et al., 2008; Meyding-
Lamade et al., 1998). Both TNFα and nitric oxide have antiviral activities but can directly generate 
potent free radicals or ROS-mediated oxidative damage through different cell signalling pathways. 
Therefore, the host’s immune and inflammatory response plays an important role in the generation 
of oxidative damage in the brain during HSV-1 infection (Valyi-Nagy et al., 2005). In conclusion, 
although few reports exist on the interplay of OS and HSV-1 infection, the results suggest that OS 
may promote the neurodegenerative events associated to HSV-1 infection. 
INTRODUCTION 
 
27 
 
3. The lysosomal pathway 
Lysosomes were first described in 1955 by Christian de Duve and thought to be just the 
cellular waste bags. They are the major digestive compartments within cells and are involved in 
multiple functions like the degradation and recycling of intra- and extracellular material, 
cholesterol homeostasis and cell death signalling (Appelqvist et al., 2013). Lysosomes have an 
acidic lumen, limited by a 7-10 nm thick phospholipid bilayer membrane, and contain several types 
of hydrolases for the degradation of substrates. There are 25 lysosomal membrane proteins (Lubke 
et al., 2009) being the lysosome-associated membrane protein (LAMP) 1 and LAMP2, lysosomal 
integral membrane protein (LIMP) 2, and LIMP1 (also known as CD63) the most abundant ones 
(Eskelinen et al., 2003). Because the low lysosomal pH provides optimal conditions for hydrolase 
activity, those proteins are protected from cleavage by dense glycosylation. Besides being a 
mechanical border, the lysosomal membrane has many other features, like the maintenance of the 
pH gradient between lysosomal lumen and cytoplasm, the mediation of fusion with endosomes or 
other organelles, and the selective transport of material into and/or out of the lysosome (Eskelinen 
et al., 2003; Saftig et al., 2009).  
Inside the lysosome reside more than 60 different soluble hydrolases, including 
sulphatases, glycosidases, peptidases, phosphatases, lipases and nucleases, most of them only 
active at acidic pH. The best-studied hydrolases are the cathepsins (CTSs). They are categorised in 
three groups based on the amino acid at their active site: serine, cysteine, and aspartic CTSs. 
Aspartic CTSs include CTS D and E, cysteine CTSs include CTS B, C, F, H, K, L, O, S, V, X and 
W, whereas CTS A and G belong to the serine CTSs (Turk et al., 2012).  
Lysosomal hydrolases are synthesized in the ER as immature and enzymatically inactive 
precursors. They are then transported in vesicles from the ER through the Golgi to the TGN and 
from there to the lysosome. To be targeted to lysosomes, a mannose 6-phosphate (M6P) tag is 
added in the Golgi complex (Rohrer et al., 2001). This signal is recognised by diverse M6P 
receptors in the TGN (Braulke et al., 2009; Ghosh et al., 2003). There, clathrin-coated vesicles 
were formed containing the receptor-ligand complexes. These vesicles move towards the cell 
periphery and fuse with endosomes. Inside the endosome, the hydrolases were dissociated from the 
receptors because of the low pH (around pH 6) and the receptors will be transported back to the 
TGN(Braulke et al., 2009). The constant trafficking of material from the TGN to the endosomes 
and back is an important feature for the maintenance of lysosomal intactness, acidity, and 
perinuclear localization (Bucci et al., 2000). The decreasing intraluminal pH during endosomal 
maturation initiates hydrolase activity and digestion of endocytosed material. However, only after 
fusion with lysosomes, the hydrolases have reached their final destination with maximal proteolytic 
activity. 
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A constant lysosomal pH between 4.8-5.2 is guaranteed by the action of an ATP-dependent 
proton pump—the vacuolar (V)-ATPase (Toei et al., 2010). V-ATPases are multi-subunit protein 
complexes consisting of a membrane-associated V0 complex that serves as a transmembrane pore 
for protons, and a soluble cytosolic V1 complex. Beside the maintenance of lysosomal pH, the  
V-ATPase also regulates vesicle fusion and is located to several membranes including lysosomes, 
endosomes, Golgi-derived vesicles and sometimes even to the plasma membrane (Yamamoto et al., 
1998; Yoshimori et al., 1991). Several potent and selective inhibitors have been identified over the 
years to interfere with this tightly regulated network. Ammonium chloride or chloroquine are 
lysosomotropic weak bases, which elevate the pH by entering the acidic compartment in their 
unprotonated form and titrating the pH upward (Ohkuma et al., 1978). Bafilomycin A1, in contrast, 
is a specific V-ATPase inhibitor (Bowman et al., 1988).  
There are two routes by which material for degradation reaches the lysosome: (i) 
extracellular material and parts of the plasma membrane reach the lysosome by endocytosis, 
whereas (ii) intracellular material is transported to the lysosome through autophagy. 
3.1. Endocytic pathway 
Endocytosis is a process by which cells internalize the plasma membrane along with cell 
surface receptors and soluble molecules (Maxfield et al., 2004). As a first step, the material to be 
ingested is progressively enclosed by parts of the plasma membrane, which invaginates and then 
pinches off to form an endocytic vesicle. These vesicles then fuse with early endosomes, the first 
sorting station of endocytosis. From there, the majority of the cargo is recycled back to the plasma 
membrane via recycling endosomes. Every hour, 50% of the surface area of the plasma membrane 
is cycled in and out of a typical mammalian cell (Steinman et al., 1983). Otherwise, cargo will be 
retained in the early endosomes, which mature into late endosomes—the second sorting station. 
During maturation several events take place, amongst other things the formation of intraluminal 
vesicles (ILVs) from the limiting membrane. The presence of many ILVs inside the late endosomes 
(often up to >30) got them the name of multivesicular bodies (MVBs) (Piper et al., 2007). Further, 
the decrease in luminal pH is taking place during this transformation from early (pH 6.8-5.9) to late 
endosomes (pH 6.0-4.9). The continuous transformation, fusion and fission of these organelles 
make their identification with molecular markers difficult. The early endosomal antigen 1 (EEA1) 
is widely accepted as marker for early endosomes (Mu et al., 1995). Late endosomes differ from 
lysosomes by the presence/absence of M6P receptors, respectively (Brown et al., 1986). 
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3.2. Autophagy 
Autophagy is the process by which cells digest their own cytoplasm to provide material for 
new synthesis. There exist three forms of autophagy in the cell: chaperone-mediated autophagy 
(CMA), microautophagy, and macroautophagy. CMA, as indicated by its name, includes the 
recognition of the substrates via the action of chaperones and the lysosomal receptor LAMP2A 
(Kaushik et al., 2012). The direct engulfment of small cytoplasmic material by the lysosomal 
membrane is called microautophagy (Li et al., 2012). The principal form of autophagy, though, is 
macroautophagy, herein referred to as autophagy.  
Autophagy begins with the formation of a double-layered isolation membrane (also called 
phagophore) that engulfs and sequesters cytoplasmic material in its interior. The elongation of this 
phagophore assures the formation of a double-membraned structure, the so-called autophagosome 
(Nakamura et al., 2017). The most characterized protein associated with autophagosomes is the 
lipidated form of microtubule-associated protein light chain 3 (LC3-II). The conversion of LC3-I 
(the non-lipidated form) to LC3-II is the main marker for monitoring autophagic flux (Klionsky et 
al., 2016). The autophagosome subsequently might fuse with endosomes or directly with lysosomes 
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for the degradation and recycling of their cargo. In this way, the degraded products are released 
into the cytoplasm to newly synthesize macromolecules or serve as energy source. There is always 
a basal activity of autophagy present to maintain cellular homeostasis acting as an essential 
mechanism of quality control for cellular structures. However, autophagy can be activated through 
diverse stimuli, like stress, low nutrient levels or viral infections, participating in multiple processes 
such as cell differentiation, innate and adaptive immunity and anti-tumoral and anti-aging 
mechanisms (Yin et al., 2016). In this scenario, the coordinated lysosomal expression and 
regulation (CLEAR) gene network gets activated through the inhibition of the mammalian target of 
rapamycin (mTOR) signalling—the main regulatory pathway of the autophagic process. Inhibition 
of mTOR dephosphorylates the master regulator of the CLEAR network—the transcription factor 
EB (TFEB) (Settembre et al., 2013). This induces its nuclear translocation, where TFEB activates 
gene transcription of more than 500 targets involved in lysosome biogenesis and autophagy. 
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3.3. Lysosomal alterations and neurodegeneration 
Neurons especially rely on functional lysosomal degradation (endocytic and autophagic 
pathways) since they live extremely long without cell division. It is therefore not surprising that 
defects in autophagy and endocytosis are relevant to neurodegenerative diseases, in particular to 
AD (Whyte et al., 2017). Indeed, altered endocytosis is one of the earliest neuropathologic features 
observed in AD preceding Aβ accumulation (Cataldo et al., 2000). The presence of autophagic 
vesicles was detected in dystrophic neurites of cortex and hippocampus in brains of transgenic mice 
expressing human APP (Yu et al., 2005). These vesicles contained APP, different Aβ peptides, and 
β- and γ-secretases necessary for their generation (Yu et al., 2004). In this sense, autophagic 
activation significantly increases Aβ production in mouse fibroblasts (Yu et al., 2005) and in rat 
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neurons (LeBlanc et al., 1996). The generated Aβ is targeted to the lysosome for degradation by 
cathepsins. Thus, efficient autophagy plays a protective role against Aβ-induced neurotoxicity in 
human neuroblastoma cells (Hung et al., 2009). Further evidence came from the discovery of 
genetic risk factors and their molecular mechanisms. FAD-causing mutations in PSEN1 severely 
compromise autophagy-mediated recycling of proteins, affecting autophagy-dependent processes 
such as APP processing and Aβ accumulation (Nixon, 2006). Finally, several studies point to 
lysosomal acidification defects in different AD models causing a failure in lysosomal proteolysis 
(Avrahami et al., 2013; Nixon et al., 2011; Torres et al., 2012). 
Support also comes from knowledge about lysosomal storage diseases (LSDs). LSDs are a 
family of disorders that result from recessively inherited gene mutations that perturb lysosomal 
homeostasis. Age of onset and clinical features vary, depending on the nature of accumulating 
substrate and the cell types affected. Common to all LSD though is the initial accumulation of 
specific macromolecules or monomeric compounds inside organelles of the endosomal-autophagic-
lysosomal system (Platt et al., 2012). Most of LSDs result from decreased activity of acidic 
hydrolases, but few are also caused by defects in lysosomal membrane proteins or non-enzymatic 
soluble proteins (Saftig et al., 2009). Almost all LSDs present pathology of the CNS, and in some 
cases neurodegeneration occurs in multiple brain regions (thalamus, cortex, hippocampus, and 
cerebellum). For example, CTS D deficiency causes neuronal ceroid lipofuscinosis—a severe 
neurodegenerative disorder (Siintola et al., 2006). Niemann-Pick type C disease (NPC) is provoked 
by alterations of cholesterol trafficking and other lipids by the defective function/absence of either 
two endosomal proteins—NPC1 or NPC2. This leads to an accumulation of autophagic vesicles 
and finally neuronal death. Interestingly, NPC patients show typical AD lesions like NFTs, 
intracellular Aβ42 accumulation and endosome deficits (Malnar et al., 2014). Indeed, LSD and AD 
display strong phenotypic overlap, including neuronal accumulation of autophagic or lysosomal 
vesicles, dystrophic axons, ectopic dentrites, cognitive deficits, and neurodegeneration. Many 
researchers claim that AD should be included in the group of LSDs due to these similarities 
(Nixon, 2005; Wolfe et al., 2013).  
One of the mechanisms that might explain lysosomal dysfunction causing 
neurodegeneration is the alteration of cholesterol homeostasis. This disturbance is one of the 
earliest and most important aspects in AD pathology. Our group previously reported that OS 
induces cholesterol biosynthesis in neuroblastoma cells, and that polymorphisms in the 3-hydroxy-
3-methylglutaryl-CoA reductase (HMGCR)—a key gene in cholesterol metabolism—are associated 
with AD risk (Recuero et al., 2009).  
Epidemiological evidence suggests a link between serum cholesterol levels and AD 
development. It has been proposed that cholesterol-lowering drugs, such as statins, might present 
potential therapeutic effectiveness for AD. This topic is highly controversial since several reports 
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claim that statins reduce the risk of AD (Jick et al., 2000), whereas others fail to reproduce those 
indicating a neutral or even negative relationship (Zandi et al., 2005). Of special interest are the 
high levels of side-chain oxidized oxysterols, like 27-hydroxycholesterol (27-OHC), observed in 
brains of SAD patients. In contrast to cholesterol, 27-OHC is able to cross the blood brain barrier. 
This fact support the theory that hypercholesterolemia might be associated with AD risk 
(Bjorkhem, 2013). Accordingly, studies with AD patient-derived fibroblasts and peripheral blood 
mononuclear cells confirmed the presence of lipid alterations in those cells (Pani et al., 2009; Pani 
et al., 2009). Increased neuronal cholesterol levels also affect APP processing, Aβ generation and 
tau phosphorylation (Burg et al., 2013; Ghribi et al., 2006). 
APOE—the strongest genetic risk factor for SAD—encodes a highly pleiotropic 
glycoprotein involved in the transport of cholesterol and other lipids in the periphery and brain. In 
the CNS, APOE plays important roles not only in cholesterol transport but also neuroplasticity and 
neuroinflammation (Mahley et al., 2000). As mentioned previously, APOE generates 3 isoforms, 
which regulate in a different manner aggregation, capture and degradation of the Aβ peptide. The 
APOE-ε4 allele, which is associated with high low-density lipoprotein (LDL) and low high-density 
lipoprotein (HDL) levels in plasma, increases plaque formation in AD patients (Kok et al., 2009). 
This might be due to their differential affinity to the LDL receptor thereby increasing cholesterol in 
plasma and brain. Other SAD-associated genes have been identified in large GWAS studies, 
including clusterin (CLU), ATP-binding cassette transporter A7 (ABCA7), and sortilin-related 
receptor 1 (SORL1) (Karch et al., 2015). They all affect lipid metabolism though highlighting the 
involvement of this mechanism in AD pathology. 
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Oxidative stress and infection of the brain with HSV-1 have been proposed to be important 
factors in the pathogenesis of sporadic AD. Although this form of the disease is multifactorial and 
environmental factors are determining, there is no doubt that the genetic predisposition plays an 
important role. To investigate the relationships between both risk factors and to identify genes and 
pathways associated with AD, an analysis of differential expression by microarrays has been 
performed in a neuronal cell model of HSV-1 infection in the presence of oxidative stress. The 
following objectives were proposed: 
 
1. Analysis of differently expressed genes via whole genome microarrays and identification 
of modulated pathways in the cell model of infection and oxidative stress. 
2. Analysis of functional alterations of the pathways identified by the gene expression 
analysis in the cell model of infection and oxidative stress.  
3. Study of the genetic association of selected candidate genes from microarray data with AD 
in case/control samples.  
4. Study of the role of the candidate genes in the neurodegenerative events induced by  
HSV-1 and oxidative stress.  
5. Development of patient-derived induced pluripotent stem cells for validating the 
genes/pathways identified in the gene expression studies in a more physiological cell 
model. 
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1. Cell lines and cell culture conditions 
The human neuroblastoma cell line SK-N-MC used in this work was purchased from the 
American Type Culture Collection (ATCC) (No. HTB-10). SK-N-MC cells with a stable 
knockdown of LAMP2 were produced in-house as described in section 4. SK-N-MC cells stably 
transfected with human wildtype (wt) APP695 (SK-APP) or mutant APP695 harbouring the 
Swedish mutation (K670N/M671L) (SK-APPSwe) were prepared in-house by M Recuero and 
commercialised by NeuronBio. All SK-N-MC cells were grown as monolayers in minimal Eagle’s 
medium (MEM) supplemented with 10% heat-inactivated fetal calf serum (FCS), 1 mM sodium 
pyruvate, non-essential amino acids (NEAAs), 2 mM glutamine, and 50 µg/mL gentamycin.  
The African green monkey epithelial kidney cell line Vero (ATCC No. CCL-81) and the 
human epithelial adenocarcinoma cell line HeLa (ATCC No. CCL-2) were passaged in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 10% FCS, 1 mM sodium pyruvate, NEAAs, 
2 mM glutamine and 50 µg/mL gentamycin.  
The murine neuroblastoma N2a cell lines (wt and with a stable knockdown of LAMP2) 
were kindly provided by P. Saftig (Rothaug et al., 2015). N2a cells were cultured in DMEM 
supplemented with 10% FCS, 1 mM sodium pyruvate, NEAAs, 2mM glutamine and  
50 µg/mL gentamycin. To the N2a LAMP2-deficient cells, 400 µg/mL G418 (Invivogen) was 
added to the media. Wt and LAMP2-deficient murine embryonic fibroblast (MEF) cells were also 
kindly provided by P. Saftig (Eskelinen et al., 2004). MEFs were cultured in DMEM-low glucose 
(1 g/L) supplemented with 10% FCS, 1 mM sodium pyruvate, NEAAs, 2 mM glutamine and  
50 µg/mL gentamycin. 
All cells were grown at 37ºC in a 5% CO2 atmosphere. 
2. Infection conditions and induction of oxidative stress 
The wt HSV-1 strain KOS 1.1 was cultivated, propagated and titered on a monolayer of 
Vero cells following described methods (Carrascosa et al., 1982) and stored at -70°C. For infection 
experiments, cells were seeded in complete media at 70-80% confluency and exposed to HSV-1 at 
37°C for 1 h. Mock infections were performed using a virus-free suspension. In order to remove 
unbound virus, the medium was changed and cells were incubated in complete medium at 37ºC. 
Time and multiplicity of infection (expressed in plaque forming units per cell [pfu/cell]) are as 
indicated in each experiment. The infectious titers of HSV-1 were determined by plaque assays 
with Vero cells as previously described (Santana et al., 2012). Induction of oxidative stress was 
performed through addition of xanthine (10 µM)-xanthine oxidase (50 mU/mL) (X-XOD) to fresh 
medium. Exposure times are indicated in each experiment. In samples exposed to oxidative stress 
and HSV-1, X-XOD was added after the virus adsorption and maintained until the end of infection. 
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3. Treatments 
Epidermal growth factor (EGF; 40 ng/mL) was purchased from Calbiochem. Xanthine 
oxidase (50 mU/mL) was purchased from Roche. Heparin (10 µg/mL), bafilomycin A1 (100 nm), 
and xanthine (10 µM) were purchased from Sigma. 4',6-diamidino-2-phenylindole (Dapi; 5 µg/mL) 
and ammonium chloride (NH4Cl; 20 mM) were obtained from Merck. For nutrient starvation, 
culture medium was exchanged for Earle’s balanced salt solution (EBSS). 
4. Generation of cell lines with stable gene-silencing of LAMP2 
For the generation of cell lines with a stable knockdown of LAMP2, cells were transfected 
with short hairpin RNA (shRNA) clones specific to LAMP2 and with a scrambled control shRNA 
clone (Mission control shRNA library from Sigma; listed in Table 1). The five specific shRNA 
clones are validated and reach more than 90% knockdown. Transfections were performed with 
Lipofectamine 2000 reagent according to the manufacturer’s recommendations (Life 
Technologies). Briefly, SK-N-MC cells were cultured in 6 well plates until 70% confluency and 
then transfected by the mixture of 0.5 µg DNA and 2 µL Lipofectamine transfection reagent, both 
diluted in Opti-MEM medium. The mixture was incubated for 5 min at room temperature (RT) to 
form DNA-lipid complexes and was then added to the cells. 48 h after transfection, cells were 
trypsinized and re-plated at low densities (dilutions 1:50, 1:500, 1:5,000) in P100 dishes with the 
selection antibiotic puromycin at a final concentration of 0.25 µg/mL (the effective concentration 
was previously determined in a dose-response experiment with SK-N-MC cells and puromycin 
concentrations between 0 and 10 µg/mL). Medium supplemented with puromycin was replaced 
every 2-3 days. Clones were picked manually and expanded until enough cells were available for 
generating a frozen stock and for isolating total RNA and protein extracts for analysis. Finally, 
clones with a low expression of LAMP2 were selected for further analyses. 
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5. Analysis of cell viability 
The extent of cell injury was evaluated using the 3-(4,5-dimethyl-thiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT; Sigma) assay (Hansen et al., 1989). Briefly, cells were seeded 
in 96 well plates, and 2 h before the end of treatment incubated with 0.5 mg/mL MTT at 37ºC. The 
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MTT/formazan released from the cells during overnight (ON) incubation at 37ºC with 100 µL 
extraction buffer (20% sodium dodecyl sulphate [SDS], 50% formamide adjusted to pH 4.7 with 
0.02% acetic acid and 0.025 N HCl) was determined. Optical densities were measured at 550 nm 
using a microplate reader (Bio-Rad, Model 680). 
6. Immunoblot 
Cells were harvested and lysed in RIPA buffer (50 mM Tris-HCl pH 7.5, 1% Triton X-100, 
150 mM NaCl, 1 mM EDTA and 0.1% sodium deoxycholate) containing a protease inhibitor 
cocktail (Complete Mini, Roche). For tau analysis a phosphatase inhibitor cocktail (PhosSTOP, 
Roche) was also added. Cell lysates were incubated at 4°C for 30 min and centrifuged at 13,000g 
for 15 min at 4ºC. The protein concentration of the lysates was quantified by the bicinchoninic acid 
assay (BCA) according to the manufacturer’s instructions (Pierce). Cell lysates were mixed with 
Laemmli loading buffer (25 mM Tris-HCl pH 6.3, 10% glycerol, 2% SDS, 5% beta-
mercaptoethanol [β-ME], and 0.01% bromophenol blue) and incubated at 100°C for 4 min. Protein 
separation was performed using Laemmli discontinuous SDS-polyacrylamide gel electrophoresis 
with variable acrylamide concentrations of the resolving gel based on the molecular weight of the 
protein of interest. To define the size of the proteins separated by electrophoresis the molecular 
weight markers Precision Plus Protein Standards Dual Color (Bio-Rad; 250, 150, 100, 75, 50, 37, 
25, 20, 15 and 10 kDa) were loaded. Gels were then transferred by semi-dry (30 min at RT) or wet 
transfer (ON at 4ºC) to a nitrocellulose membrane with a pore-size of 0.45 µm (Bio-Rad). Total 
protein stain with Ponceau S was performed to check for transfer efficiency. Membranes were 
subsequently blocked ON at 4ºC in 3% BSA and 0.2% Tween-20 in phosphate-buffered saline 
(PBS) and incubated with the primary antibody diluted in PBS, 1% BSA and 0.1% Tween-20. 
After washing in PBS, 0.05% Tween-20, the blots were incubated with the corresponding 
horseradish peroxidase (HRP)-coupled secondary antibodies. Alternatively, blots were blocked 1 h 
at RT in 5% milk and 0.1% Tween-20 in tris-buffered saline (TBS) and incubated with the primary 
and secondary antibody diluted in TBS, 5% milk and 0.1% Tween-20. All used antibodies and their 
dilutions are listed in Table 2. Immunodetection was performed using ECLTM Western blotting 
Detection Reagents according to manufacturer’s instructions (GE Healthcare Life Sciences). To 
quantify the intensity of protein band, densitometric analysis was performed using the Quantity 
One® Software (Bio-Rad). 
7. Immunocytochemistry 
Cells grown on coverslips were fixed with 4% formaldehyde for 10 min at RT and washed 
3 times with PBS for 5 min. Fixed cells were then permeabilized and blocked ON at 4ºC with a 
blocking solution containing 0.2% Triton X-100 and 2% horse serum in PBS (pH 7.4), followed by 
incubation with the corresponding primary antibody (Table 2) for 90 min at RT diluted in blocking 
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solution. After 3 washing steps in blocking solution for 5 min at RT, cells were incubated with 
Alexa Fluor-coupled secondary antibodies for 90 min at RT and protected from light. Cells were 
counterstained with Dapi (5 µg/mL) in PBS for 10 min at RT to visualize the nuclei, followed by 3 
more washing steps in PBS. Afterwards, coverslips were washed in water and dehydrated in 100% 
EtOH. Finally, coverslips were mounted with Mowiol mounting medium (Sigma) on a microscope 
slide.  
Cells were examined using an Axiovert200 or LSM710 confocal microscope (both from 
Zeiss) and a 63x oil-immersion objective controlled by MetaMorph® 7.10 (Molecular Devices) 
and ZEN 2010 software (Carl Zeiss Microscopy GmbH), respectively. Images were processed 
using Adobe Photoshop CS4. 
8. Antibodies 
8.1. Primary antibodies 
All primary antibodies and their dilution factors used are listed in Table 2. 
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8.2. Secondary antibodies 
The secondary antibodies used for immunostaining were HRP-coupled antibodies (Vector; 
dilution 1:50,000), or antibodies labelled with Alexa Fluor 488 or 555 dyes (Invitrogen; dilution 
1:1,000). 
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9. Viral DNA quantification by real-time quantitative polymerase chain reaction (qPCR) 
DNA was extracted using the QIAamp® DNA Mini Kit (QIAGEN) as previously 
described (Burgos et al., 2006). The concentration of viral DNA was then quantified by qPCR with 
an ABI Prism 7900HT SD® system (Applied Biosystems) using a custom designed TaqMan probe 
specific for the US12 viral gene (5’-AGGCGGCCAGAACC-3’). Viral DNA content was then 
normalized in terms of human genomic DNA, quantified with a predesigned TaqMan probe 
specific for the 18S gene (Applied Biosystems). The quantification results were represented as viral 
DNA copy numbers per ng of genomic DNA. 
10. Quantification of mRNA by reverse transcription followed by real-time PCR (RT-
qPCR) 
Total RNA was purified with the High Pure RNA Isolation kit according to the 
manufacturer’s instructions (Roche). To determine the RNA quantity, samples were analysed with 
a NanoDrop® ND-1000 (NanoDrop Technologies). Complementary DNA (cDNA) was obtained 
from 0.5 µg of RNA by reverse transcription using the High Capacity RNA to cDNA Archive Kit 
(Applied Biosystems). Real-time PCR was carried out with an ABI Prism 7900HT SD® (Applied 
Biosystems) using TaqMan assays (in individual or in array format) or specific primers for the 
genes listed in Table 3. The target-specific primer sequences were designed by using the 
ProbeFinder Assay Design Software (Roche). Samples were normalized with respect to the value 
obtained for the 18S or GAPDH gene due to its constant expression. 
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11. Measurement of secreted Aβ 
For secreted Aβ analysis, conditioned media of N2a and MEF cells were collected and 
centrifuged at 1,000g for 10 min. Viral particles of supernatants were inactivated by ultraviolet 
irradiation. Because of the lower Aβ levels in conditioned media of MEF cells, those were stored at 
-80°C and concentrated 5-fold by lyophilization. The media was then assayed for murine Aβ40 and 
Aβ42 using commercial sandwich enzyme-linked immunosorbent assay (ELISA) kits according to 
the manufacturer’s instructions (WAKO). Briefly, media was added to ELISA plates pre-coated 
with monoclonal antibodies specific for the murine Aβ (the capture antibody), followed by an 
antibody specific for the amino acid sequence (amino acids 1-40 or 1-42) of Aβ (the detection 
antibody) labelled with HRP. The detection antibody bound was quantified measuring the 
absorbance at 450 nm within 30 min of the completion of the procedure. Values were normalized 
with the Aβ standard curve and expressed in pg/mL. 
12. Quantification of lysosomal cellular content 
12.1. Flow cytometry 
Lysosomal burden was evaluated using the acidotropic probe LysoSensor® Green DND-
189 (LSG; Molecular Probes). This probe freely passes through cell membranes and typically 
concentrates in acidic organelles. 1 h before the end of treatments, cells were loaded with 0.1 µM 
LSG for 1 h at 37°C in culture medium. Cells were then washed with PBS and fixed with 2% 
formaldehyde. After washing twice with PBS, cells were subjected to flow cytometry analysis by 
counting 10,000 events with a FACS Calibur flow cytometer (BD Biosciences). LSG fluorescence 
intensity was recorded in the FL-1 channel (530/30 nm) with the CellQuest Pro software (BD 
Biosciences). Data were analysed using the FlowJo® software. 
12.2. Fluorogenic enzyme assay 
Lysosomal burden was also evaluated using the acidotropic probe Lysotracker® Red 
DND-99 (LTR; Molecular Probes). 1 h before the end of treatments, cells were loaded with 1 μM 
LTR for 1 h at 37°C in culture medium and were then washed with PBS. Cells were lysed with 
RIPA buffer for 30 min at 4ºC and the lysates were centrifuged at 13,000g for 10 min. The protein 
concentration of the lysates was quantified by the BCA method and the fluorescence of 50 µg of 
total protein was recorded using a FLUOstar® OPTIMA microplate reader (BMG LABTECH) 
with excitation at 560 nm and emission at 590 nm. 
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13. Assessment of lysosomal enzyme activity 
13.1. Measurement of cathepsin activities 
The enzymatic activity of several cathepsins (CTSs) was determined as previously 
described with minor modifications (Porter et al., 2013). Briefly, 25-75 µg of protein from cell 
lysates were incubated for 30 and 60 min in the presence of the following fluorogenic substrates 
(all from Enzo Life Sciences): Z-VVR-AMC (most sensitive substrate for CTS S; 20 µM), Z-GPR-
AMC (specific for CTS K; 20 µM), Z-RR-AMC (specific for CTS B; 20 µM) and CTS D and E 
fluorogenic substrate (10 µM). These synthetic substrates have a 7-amino-4-methylcoumarin 
(AMC) tag next to the cleavage site. While attached to the substrates, its fluorescence is quenched. 
Cleavage of the AMC peptide generates strongly fluorescent AMC that can be monitored 
fluorimetrically. The fluorescence of AMC released as a result of proteolytic activity was 
quantified with a microplate reader (Tecan Trading AG) with excitation at 360 nm and emission at 
430 nm (Z-VVR-AMC, Z-GPR-AMC and Z-RR-AMC) or with excitation at 320 nm and emission 
at 400 nm (CTS D and E fluorogenic substrate).  
13.2. Measurement of β-hexosaminidase activity 
As a substrate for β-hexosaminidase activity, the artificial, chromogenic substrate  
4-nitrophenyl-N-acetyl-β-D-glucosaminide was used (Sigma). Briefly, 10 µL of protein lysates 
were incubated for 60 min with 10 mM substrate in 100 µL assay buffer (0.2 M trisodium citrate 
pH 4.6, 0.4% BSA, and 0.08% sodium azide) at 37°C. Hydrolysis was stopped by adding 0.5 mL 
of 0.4 M glycine solution (pH 10.4). Samples were then centrifuged at 16,000g for 10 min at RT. 
The proteolysis of the substrate leads to the generation of 4-nitrophenol, which was determined 
spectrophotometrically by measuring the absorbance at 405 nm with a microplate reader (Synergy 
HT from BioTEK). Specific enzymatic activity is expressed as nmol of released 4-nitrophenol per 
hour and mg protein.  
14. EGF receptor degradation assay  
HeLa cells were cultured in serum free medium for at least 6 h before the treatments with 
HSV-1 and X-XOD. After HSV-1 adsorption/X-XOD addition, cells were incubated with medium 
containing 2% FCS. To stimulate EGF receptor (EGFR) endocytosis, EGF (40 ng/mL) was added 
at the times indicated in each experiment. Cells were collected at various time points and levels of 
EGFR analysed by Western blot (see section 6) or immunofluorescence (section 7). For EGFR 
experiments in SK-N-MC, cells were first transfected with a myc-tagged EGFR expression plasmid 
(pEGFR-c-myc) using the JetPEI DNA transfection reagent according to the manufacturer’s 
recommendations (Polyplus transfections). Briefly, cells were cultured in P100 dishes until 70% 
confluency and then transfected by the mixture of 15 µg DNA and 30 µL JetPEI transfection 
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reagent, both diluted in 150 mM NaCl. The JetPEI/DNA mix was incubated for 25 min at RT and 
then added dropwise to the dishes with fresh medium. After 24 h, the cells were trypsinized and 
seeded in 24 well plates for EGF treatment and HSV-1 infection as previously described. After the 
treatments, levels of EGFR-c-myc in cell lysates were analysed by Western blot using an antibody 
specific for the myc epitope. 
15. Partial purification of lysosomes 
The partial purification of lysosomes was performed as previously described with minor 
modifications (Avrahami et al., 2013). Briefly, cells were washed once in PBS, collected with wash 
buffer (125 mM KCl, 30 mM Tris pH 7.5, 5 mM MgOAc, 1 mM β-ME) and centrifuged at 800g 
for 5 min. Cells were resuspended in hypotonic buffer (10 mM KCl, 30 mM Tris pH 7.5, 5 mM 
MgOAc, 1 mM β-ME, protease inhibitor cocktail) and broken with a 23G needle by 15 strokes 
(fraction F0: total cellular lysate). Homogenates were centrifuged at 1,000g for 5 min to precipitate 
nuclei. The supernatants (nuclei-free lysate: fraction F2) were again centrifuged at 100,000g for 1 h 
at 4ºC. The supernatant was stored (cytosolic fraction F3) and the pellet (membrane fraction 
including lysosomes: fraction F4) was lysed in RIPA buffer containing protease and phosphatase 
inhibitors. Protein concentration of the lysates was quantified by the BCA method.  
16. Cholesterol quantification 
The levels of cellular cholesterol were quantified enzymatically using the Amplex Red 
Cholesterol Assay kit following the manufacturer’s instructions (Invitrogen). This method is based 
on enzyme-coupled reactions that allow detection of both—free and esterified—cholesterol. In our 
experiments only free cholesterol was measured (lack of cholesterol esterase in the reaction mix). 
Free cholesterol is oxidized by the enzyme cholesterol oxidase generating hydrogen peroxide 
(H2O2) and the corresponding ketone product. H2O2 is detected by the 10-acetyl-3,7-
dihydroxyphenoxazine (Amplex Red reagent). In the presence of HRP, H2O2 reacts with Amplex 
Red to produce the fluorescent compound resorufin, which can then be quantified. To perform the 
assay, 10 µg of total cell lysates or 5 µg of partially purified lysosome fractions were diluted in 
Reaction Buffer and incubated with Amplex Red working solution (Amplex Red 
reagent/HRP/cholesterol oxidase) for 30 min at 37°C. Fluorescence values at an excitation 
wavelength of 570 nm and an emission wavelength of 585 nm were measured with a microplate 
reader, normalized to control samples and expressed in percentages. 
17. Filipin labelling of membrane cholesterol 
To monitor cholesterol by fluorescence microscopy, cells were fixed with 4% 
formaldehyde, washed with PBS and incubated for 1 h with filipin (50 µg/mL)—a fluorescent 
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polyene antibiotic that binds free cholesterol. Cells were washed again with PBS and mounted with 
Mowiol mounting medium on microscope coverslips. Images were taken using an Axiovert200 
microscope (Zeiss) with a 63x oil-immersion objective and processed with Adobe Photoshop CS4.  
18. Expression microarrays: Gene quantification and functional annotations 
18.1. RNA extraction and hybridization to the arrays  
Total RNA of SK-N-MC cells was obtained using a commercial kit (High Pure RNA 
isolation kit from Roche). RNA was then sent to a platform associated with the National Center of 
Genotyping (GENOMA ESPAÑA) in the Centro de Investigaciones Cardiovasculares (CNIC). 
Samples were hybridized to a Whole Human Genome Microarray 4x44K (G4112F from Agilent 
Technologies). Arrays were scanned at 5 ?M resolution on an Agilent DNA Microarray scanner 
(G2565BA from Agilent Technologies) using the default settings for 4x44K format one-color 
assays. Provided Images were analysed using Feature Extraction software v10.7 (Agilent 
Technologies).  
18.2. Data analysis 
Raw signals were thresholded to 1 and quantiles normalization (Bolstad et al., 2003) was 
performed using the software GeneSpring v11. Data were considered in the log2 scale. Default 
flags were considered as absent, except saturated points that were flagged as marginal. The 
following filters were applied: (I) Expression: Genes with at least all replicates in 1 out of 6 
conditions of all the samples within the accepted intensity range were retained, (II) Flags: Genes 
with at least all replicates in 1 out of 6 conditions with the reliable values (Present and Marginal 
Flags) were retained, and (III) Error: Only those genes that change across the experiment, i.e. with 
coefficient of variation >1% across all samples were retained. For statistical analysis the limma 
package (Bioconductor) for differential gene expression was used (Smyth, 2004). It calculates 
moderated t-statistics, adding to the error term some information on the variance of all genes, 
solving the typical microarray problem of small size. Those probes with a corrected p-value <0.05 
were considered as differentially expressed. 
18.3. Functional enrichment of differentially expressed genes by GeneCodis and IPA 
Genes that were differentially expressed were uploaded to bioinformatic tools for posterior 
data mining. Gene annotations co-occurrence discovery (GeneCodis; genecodis.cnb.csic.es) and 
Ingenuity Pathway Analysis (IPA; Ingenuity® Systems, www.ingenuity.com) were used to identify 
pathways and functions significantly over- or underrepresented in the gene lists compared with the 
whole human genome. 
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19. Genetic association study 
19.1. Study subjects 
The study sample included 587 patients with sporadic AD (mean age at onset 73 ± 8 years; 
range 55-109 years; 65% women) who met NINCDS/ADRDA criteria for probable AD (McKhann 
et al., 1984). All AD cases were defined as sporadic because their family history did not mention 
any first-degree relative with dementia. AD patients were recruited from the Departments of 
Neurology of the Hospital La Paz (Madrid, Spain), ISCIII Collection (C.0002965) and the Hospital 
Marques de Valdecilla (Santander, Spain). Control subjects were 615 unrelated individuals (mean 
age at examination 77 years ± 9.6 years; range 55-104 years; 67% women). These subjects were 
free of significant illness and had Mini Mental State Examination scores of 27 or more. The 
controls arose from the same base population as the cases and both groups were of Caucasian 
origin. All subjects gave their informed consent to be included in the study, which was approved by 
the Ethics Committees of the participating institutions. 
19.2. Genotyping 
Genotyping was performed with predesigned assays (TaqMan SNPs OpenArrays; Applied 
Biosystems) according to manufacturer instructions and genotypes were assigned with the TaqMan 
Genotyper Software (Applied Biosystems). Genotypes and allele distributions were compared 
using the χ2 test (crude analysis) and in logistic regression models adjusting for age at AD onset, 
gender and APOE genotype. SPSS v.19.0 software was used for all statistical analyses.  
19.3. SNP selection 
TagSNPs were selected to cover 80% of the variability of the genes of interest (LAMP2, 
NPC1 and CTSF) in the CEU population (Utah residents with Northern and Western European 
ancestry) included in the HapMap project. The tagSNPs representative of each haplotype block 
were chosen based on genotyping probe availability (TaqMan assays from Applied Biosystems), 
minor allele frequency (MAF>5%), linkage disequilibrium (r2>0.8) and, when possible, predicted 
functional effect. The SNPinfo tool (https://snpinfo.niehs.nih.gov/cgi-bin/snpinfo/snptag.cgi) was 
used for the selection. For the LAMP2 gene, an additional SNP in the promoter region (rs42901) 
was included based on its potential effect on the binding of transcription factors, although it was 
represented in the Yoruba but not in the CEU population. 
At the end of this work, the tagSNPs originally chosen from the HapMap CEU population 
were restudied in the Iberian population included in the 1000 Genomes project located in the 
ENSEMBL server (human genome version GRCh37.p13) (http://www.ensembl.org/ 
Homo_sapiens/Info/Index?db=core). We found no major differences in the haplotype architecture 
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between the Iberian and CEU populations indicating that the selected tagSNPs were actually valid 
for our study sample. However, some exceptions were found, like stronger linkage disequilibrium 
between the LAMP2 SNPs rs7889047 and rs42892 in the Iberian (pairwise r2 0.62) compared to the 
CEU population (r2 0.35), illustrating the possibility that genetic background of AD varies among 
populations. 
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20. Generation of induced pluripotent stem cells (iPSCs) 
Procedures for sample collection and iPSC line generation were approved by the 
Institutional Ethics Committee (Hospital Universitario La Paz and Universidad Autónoma de 
Madrid) and informed consent was obtained from the patients. 
20.1. Cell culture media 
20.1.1. Fibroblast medium 
DMEM supplemented with 10% fetal bovine serum (FBS) HyClone, 2 mM GlutaMAX,  
50 mg/mL gentamycin, and 0.1 mM NEAAs. Media was stored at 4ºC in the dark and used within 
1 month. 
20.1.2. MEFs medium 
Iscove’s Modified Dulbecco’s Medium (IMDM) supplemented with 10% FCS, 2 mM 
glutamine and 50 mg/mL gentamycin. Media was stored at 4ºC in the dark and used within 1 
month. 
20.1.3. iPSC medium 
KnockOut DMEM supplemented with 10% KnockOut Serum Replacement, 0.5% human 
serum albumin (HSA), 2 mM GlutaMAX, 50 mg/mL gentamycin, 0.1 mM of each NEAA, 55 µM 
β-ME, 100 µg/mL basic fibroblast growth factor (bFGF). Medium was filtered through a 0.22 µM 
filter, stored at 4ºC in the dark and used for up to 1 week. 
20.2. Establishing primary cell cultures from patient biopsies 
A 6 mm skin punch biopsy was obtained by a trained physician from the inner side of the 
forearm from an AD patient and an age-matched control. The skin specimens were placed in a 50 
mL conical tube containing ~25 mL of sterile complete fibroblast media at RT for shipment to the 
laboratory and stored ON. Within 24 h, the biopsy specimens were cut using sterile forceps and 
scissors into 20-30 pieces of ~1-3 mm size. The pieces were then transferred onto the surface of a 
T25 flask and incubated with complete fibroblast media at 37ºC, 5% CO2 for 14 days. Medium was 
changed twice a week. After 21-28 days, human dermal fibroblasts (HDFs) were passaged and 
frozen at passage 2 in freezing media (90% FCS, 10% DMSO) ON at -80ºC using a cryo 1ºC-
freezing container, before transferring the frozen vials to liquid N2 for long-term storage. 
20.3. Generation of a stock of irradiated mouse embryonic fibroblasts 
MEF cells from 12 x P150 dishes were harvested and centrifuged at 800g for 5 min at RT. 
The cells were then resuspended in fresh MEF medium and irradiated at 80 Grays. Subsequently, 
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irradiated cells were centrifuged at 800g for 5 min at RT and frozen in freezing media as previously 
described. 
20.4. Sendai viral transduction of fibroblasts and generation of iPSCs 
HDFs were collected and cultured from a patient and an age-matched control as described 
previously in section 20.2. iPSCs were generated using integration-free CytoTune®-iPS 2.0 Sendai 
Reprogramming Kit including Sendai virus particles expressing the four Yamanaka factors OCT4, 
SOX2, KLF4, and cMYC according to the manufacturer’s protocol (Invitrogen). Briefly, 2.5 x 105 
HDFs were plated onto one well of a 6 well plate. In a single reprogramming experiment each of 
the Sendai viruses was used to transduce the cells (Table 5) (KOS Moi=5, cMYC Moi=5, KLF4 
Moi=3). Seven days after transduction, cells were plated in P100 dishes onto irradiated MEF feeder 
cells, and fed with iPSC medium. 2-3 weeks post-transduction the colonies were selected by its 
morphology and TRA1-60 live staining and picked for expansion into individual iPSC lines. Once 
a week, each iPSC line was mechanically passaged using a Stripper micropipette (Origio) with  
150 µm capillaries (Genetics). 
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21. Characterization of iPSC lines 
21.1. Alkaline phosphatase staining 
This assay is based on the reaction of two components—bromochloroindolyl phosphate 
(BCIP) and nitro blue tetrazolium (NBT). In the presence of alkaline phosphatase (AP) a bluish-
purple product is produced. For AP staining, cells must be fixed and cannot be maintained in 
culture afterwards. Therefore, during weekly splitting, a few iPSC colonies (3-4) were seeded in  
6 well plates on irradiated MEFs and grown for approximately 5-6 days. Phase contrast images of 
the colonies were taken before the staining. Then, cells were fixed for 2 min with formalin at RT 
and washed twice with PBS. To heat-inactivate endogenous AP from MEFs, cells were incubated 
with pre-warmed PBS for 20 min at 64ºC. Then, AP staining was performed with Alkaline 
Phosphatase Blue Membrane Substrate Solution according to manufacturer’s instructions (Sigma). 
Cells were washed again to eliminate remaining AP staining solution, and phase contrast images of 
the same iPSC colonies were taken with a standard microscope (magnification: 4x or 10x). 
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21.2. TRA1-60 live staining 
To select colonies expressing TRA1-60, primary (anti-TRA1-60, 1:300) and secondary 
(anti-mouse IgM Alexa Fluor 555, 1:200) antibodies diluted in iPSC media were added to the cells 
(3 mL per 100 mm dish) and incubated for 1 h at 37ºC. To remove any unbound antibodies, cells 
were washed once with PBS and incubated with fresh media for 15 min at 37ºC. Cells were then 
visualized under a standard fluorescent microscope. TRA1-60 positive colonies were selected for 
expansion. 
21.3. Immunofluorescence analysis 
To confirm the pluripotency of iPSC colonies by immunostaining, 3-4 colonies were 
seeded on irradiated MEFs in each well of a chambered coverslip (Ibidi). After 7 days, colonies 
were fixed in 4% formaldehyde for 30 min, permeabilized and blocked with buffer containing  
0.3% Triton X-100 and 3% donkey serum in PBS for 1 h. Cells were then incubated with the 
appropriate primary antibodies listed in Table 6. Then, incubation with the appropriate Alexa Fluor 
488-, 555- or 647-labeled secondary antibodies (dilution 1:200) was performed for 2 h. Nuclei were 
counterstained with Dapi. Images were taken with a 25x oil-immersion objective using a Zeiss 
LSM 710 confocal microscope. 
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21.4. RT-qPCR analysis 
Total RNA was isolated using TRIZOL reagent and was then sent to the Genomic Unit of 
the Fundación Parque Científico from Madrid. Briefly, 250 ng of RNA was used to synthesize 
cDNA using the High capacity RNA to cDNA kit (Applied Biosystems). Each cDNA sample was 
amplified using SYBR Green Mix on the thermocycler LightCycler 480 (Roche). Primer sequences 
are shown in Table 7. All the expression values were normalized to the GAPDH housekeeping 
gene. 
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22. Statistical analysis 
Graph values are expressed as mean ± standard error of the mean (SEM) or standard 
deviation (SD). Unless otherwise indicated in specific experiments, differences between groups 
were analysed using the 2-tailed Student t test. Significance was recorded as *p<0.05; **p<0.01; 
***p<0.001. 
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1. Differential gene expression studies after X-XOD treatment in cell models of sporadic 
and familial AD suggest alterations of the lysosomal pathway 
Chronic infections of the CNS and oxidative stress associated with aging are important 
factors in the pathogenesis of AD (Harris et al., 2015; Persson et al., 2014). Herpes viruses are 
pathogens with high prevalence in the population and HSV-1 infection has been associated with 
SAD (Itzhaki, 2014). To study the impact of HSV-1 infection and oxidative stress on gene 
expression and identify putative genes or/and pathways associated with AD pathogenesis, a 
microarray analysis was performed in human neuroblastoma cells. To mimic the situation of 
endogenous infection in AD brains, a cell model of HSV-1 infection at a low viral dose in the 
presence of mild oxidative stress was developed. SK-N-MC cells were infected with HSV-1 for 24 
and 36 hours in the presence and absence of oxidative stress induced by X-XOD. Thus, four 
conditions were finally established: untreated cells (mock), cells subjected to oxidative stress (X-
XOD), cells infected with HSV-1 at a moi of 0.1 pfu/cell (HSV-1) and cells infected with HSV-1 
and subjected to oxidative stress (HSV-1+X-XOD) (Figure 6). The microarray analysis of a 
monogenic cell model for FAD (SK-APPSwe) exposed to OS for 24 and 36 hours was also included. 
This model was generated in-house and consists of SK-N-MC cells stably transfected with human 
APP695 harbouring a double mutation (K670N/M671L) known as the Swedish mutation. The 
name makes reference to its identification in two large Swedish families with early-onset FAD 
(Mullan et al., 1992).  
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1.1. Quality control of samples
Before the samples were processed for microarray analysis their quality must be confirmed. 
To ensure correct HSV-1 infection and X-XOD treatment, cells were harvested and samples 
prepared for two different quality control assays: (1) Immunoblot of viral and apoptosis-associated 
proteins and (2) viral qPCR. For each time point, at least three independent experiments were 
performed. 
The X-XOD system represents a free radical-generating system inducing apoptotic cell 
death and was first described in cerebellar granule neuronal cultures via ROS production (Fatokun 
et al., 2007). Our laboratory established a model of mild oxidative stress induced by X-XOD in 
human neuroblastoma cells which was used in this work (Recuero et al., 2009). To validate the 
apoptosis induced by X-XOD, Western blot analyses with the anti-p85 antibody were performed. 
Cleavage of poly ADP-ribose polymerase (PARP) by caspases is a fairly early event in apoptosis 
and the level of p85 fragment is a common apoptotic marker. As shown in Figure 7A lower panel, 
p85 was not detected in mock (24 hpi) and slightly increased in X-XOD (24 hpi), mock (36 hpi) 
and HSV-1 infected cells (24 and 36 hpi) indicating a low level of apoptosis in these conditions. 
However, oxidative stress induced a strong increase of p85 levels after 36 hours of X-XOD 
treatment indicating an induction of apoptosis at this time-point. The simultaneous infection with 
HSV-1 did not show any influence on the amount of p85 at 24 hpi but p85 levels were reduced 
compared to that observed in X-XOD treated cells at 36 hpi. These data are in agreement with the 
capacity of HSV-1 to block the apoptotic process induced by different stimuli (Aubert et al., 2001; 
Jerome et al., 2001). The results confirm an efficient induction of apoptosis by the X-XOD system. 
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To check the efficiency of HSV-1 infection, the level of the late viral glycoprotein gC was 
monitored. Western blots were performed using the anti-gC antibody. Figure 7 shows that all mock 
and X-XOD samples were virus-free, whereas HSV-1 infected cell lysates presented a pattern of 
bands corresponding to the differently glycosylated gC. The gC levels were dependent on time of 
infection. When the cells additionally were exposed to X-XOD a strong decrease of the gC levels 
was observed, particularly the highly glycosylated forms of the protein (Figure 7A upper panel). 
Another method to confirm the efficiency of HSV-1 infection is the quantification of viral 
DNA by qPCR. As expected, non-infected samples (mock and X-XOD) did not contain any viral 
DNA. HSV-1 infected cells for 24 and 36 hours presented high amounts of viral DNA (absolute 
values: 2.15x105  [24 hpi] and 1.52x106 [36 hpi] viral DNA copies per ng genomic DNA). X-XOD 
treatment significantly reduced the levels of viral DNA at both time points (24 hpi: 63% of 
reduction; 36 hpi: 91% of reduction [mean of three independent experiments]) (Figure 7B). This 
interaction between HSV-1 infection and OS has been extensively studied in SK-N-MC cells by 
our group showing that OS inhibits the generation of infectious viral particles and protects against 
cell death induced by the virus (Santana et al., 2013). 
Taken together, these results showed that HSV-1 infection and X-XOD treatment were 
efficient, all mock and X-XOD treated samples were virus-free and OS interacts with HSV-1 
infection causing a strong inhibition of infection revealed by a diminution of viral protein and viral 
DNA levels. Thus, the samples obtained are adequate to perform differential gene expression 
analysis by microarrays.  
1.2. Microarray gene expression studies of our cell models 
Total RNAs from the samples were obtained and the gene expression was analysed by 
microarrays covering the whole human genome. Compared to uninfected cells, 833 genes were 
modulated by OS in the infection cell model (HSV-1) and 158 genes in the monogenic cell model 
(SK-APPSwe) at 24 hpi (Figure 8) but not in the respective controls. In order to identify a common 
pathogenic mechanism for both models—sporadic and familial AD—the focus was set on those 
genes regulated by OS in the infection and monogenic cell models. This approach let to a list of 68 
differently expressed genes using a p-value cut-off of 0.05 (for complete list of genes see Annex I). 
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In the list of genes modulated by OS, 65 genes were found to be significantly 
overexpressed (fold change [FC]>1.5) and 3 significantly repressed (FC<0.67). To study the 
pathways associated with differently expressed genes the Gene Annotations Co-occurrence 
Discovery (GeneCodis) software was used (Carmona-Saez et al., 2007; Nogales-Cadenas et al., 
2009; Tabas-Madrid et al., 2012). Significant enrichment of the Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathway 04142: “Lysosome”, in the list of overexpressed genes was noted 
(Figure 9). Five genes of those 68, namely cathepsin F (CTSF); lipase A, lysosomal acid, 
cholesterol esterase (LIPA); ATPase, H+ transporting, lysosomal accessory protein 1 (ATP6AP1); 
Niemann-Pick disease, type C1 (NPC1); and lysosomal-associated membrane protein 2 (LAMP2), 
were annotated to the lysosomal pathway. 
To confirm the results obtained from GeneCodis, the same gene list was analysed with 
another software. Running the core analysis of the Ingenuity Pathway Analysis (IPA) software, we 
obtained as the top annotated Diseases & Functions the “lysosomal storage disease”, and then 
“metabolism of sterols” (with a p-value of 1,42E-05 and 4,78E-05, respectively). These results 
reproduce the findings obtained with the GeneCodis analysis identifying the lysosome as the main 
altered pathway and further indicating an alteration of lipid metabolism. 
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1.3. Validation of microarray results by RT-qPCR 
To confirm the microarray data, an independent gene expression profiling method is 
required. Quality control is crucial and diverse confirmation methods such as RT-PCR, northern 
blot, or in situ hybridization are valid depending on the type of experiment. RT-PCR is the method 
of choice for most researchers because of its high sensitivity. Briefly, SK-N-MC cells were grown 
on P100 plates and the same conditions as in microarray analysis were established: mock cells, 
cells treated with X-XOD, cells infected with HSV-1 and cells infected with HSV-1 and treated 
with X-XOD (Figure 6). We decided to analyse the expression of 20 selected genes because of 
their functional involvement in two KEGG pathways associated with the lysosome: (i) the 
lysosomal pathway (KEGG no. 4142; Figure 9) and (ii) the SNARE interactions in vesicular 
transport pathway (KEGG no. 4130). The expression values obtained for the genes of the 
lysosomal pathway at 24 and 36 hours modulated by either one of the conditions alone or in 
combination are shown in Figure 10. All 5 genes annotated to the lysosomal pathway showed the 
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same direction in expression levels as the microarray results. As can be observed in the figure, all 
the genes—except CTSB—were upregulated by X-XOD treatment in infected and uninfected cells, 
suggesting that the lysosomal pathway was mainly regulated by OS in our cells. However, gene 
expression continued growing at 36 h compared with 24 h in non-infected cells, whereas this 
increase did not appear in infected cells, suggesting that HSV-1 and OS actually interact in the 
regulation of the lysosomal pathway. These results pushed our interest to perform a functional 
analysis of this pathway in our cell model of neurodegeneration.
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2. HSV-1 infection and OS alter the lysosomal pathway in SK-N-MC cells 
Gene expression microarray data of oxidative stress treated samples in two cell models 
(infection and monogenic model) revealed a significant annotation of the lysosomal pathway. 
Therefore, we decided to study different aspects of this pathway in our cell models with the aim of 
investigating possible alterations induced by HSV-1 and OS. Previous work by our group reported 
that the highest effect on neurodegenerative events provoked by HSV-1 and OS is achieved with a 
moi of 10 pfu/cell for 18 hours. These conditions ensure that almost all cells are infected and are 
therefore set as the standard ones in the following experiments.  
2.1. HSV-1 and OS increase lysosomal content 
In this first part, we evaluated the effect of HSV-1 and OS on lysosomal content.  
SK-N-MC cells were exposed to HSV-1 and OS and the samples analysed by Western blot using 
specific antibodies for several markers of the endo-lysosomal system. Rab7 and LAMP1 and 2 are 
known as specific markers for late endosomes and lysosomes, respectively. HSV-1 infection and 
OS increased the amount of Rab7, LAMP1 and LAMP2 proteins compared to untreated cells. 
However, the combination of both treatments showed no synergistic effect (Figure 11). 
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Next, we decided to measure the effect of HSV-1 and OS on cellular lysosomal content 
with lysosomotropic dyes. These probes selectively accumulate in cellular compartments with low 
internal pH. LysoSensor Green DND 189 (LSG) is a pH sensitive probe that exhibits an increase or 
decrease in fluorescence intensity upon intracellular acidification or alkalinisation, respectively. 
LSG quantification by flow cytometry showed a significant increase of fluorescence intensity in 
HSV-1 infected cells (Figure 12A and B), whereas OS had no effect on LSG fluorescence. The use 
of the lysosomal inhibitor ammonium chloride—a weak base that alkalinizes the lysosome—and 
nutrient starvation—as a positive control to increase lysosomal content—confirmed the specificity 
of the assay (Figure 12C). These first results indicate that HSV-1 infection leads to an increased 
number of lysosomes. 
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To confirm the increase of the lysosomal burden in infected cells, we measured the 
fluorescence of LysoTracker Red (LTR) with a microplate reader. As LSG, LTR is a 
lysosomotropic dye, however its fluorescence is independent of pH. As shown in Figure 13A, 
HSV-1 infection significantly increased the LTR intensity, confirming the increment of cellular 
lysosomal content provoked by the virus. In contrast with LSG data, cultures subjected to OS also 
showed a strong and significant increase in LTR fluorescence indicating that OS enhances the 
lysosomal burden but could be affecting the lysosome acidity. We did not observe a synergistic 
effect when cells were cultivated in the presence of both factors. Again, bafilomycin A1—a 
specific V-ATPase inhibitor that increases lysosomal pH—and nutrient starvation—to increase 
lysosomal content—were used to confirm the specificity of the assay (Figure 13B). Taken together, 
these results suggest that HSV-1 infection and OS lead to an increase of lysosomal content in  
SK-N-MC cells. In addition, these results are consistent with the microarray data indicating that the 
increase of the expression of lysosomal genes induced by HSV-1 and OS is translated into an 
increment of endo-lysosomal protein levels and lysosomal burden. 
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2.2. HSV-1 and OS reduce the activity of lysosomal enzymes 
Given the increased lysosomal burden observed in HSV-1 infected cells, we then evaluated 
the lysosomal activity. With this aim, the enzymatic activity of several lysosomal CTSs was 
quantified. CTSs are abundant lysosomal endopeptidases that catalyse the hydrolysis of a variety of 
substrates. CTS D and E are aspartic proteases whereas CTS B, K and S are cysteine proteases. In 
these studies, fluorogenic substrates specific for each of these CTSs were used. As shown in Figure 
14, infection with HSV-1 reduced the activity of all studied CTS. Cultures treated with OS showed 
reduced activity in mock and HSV-1 infected samples. The reduction of activity provoked by OS is 
stronger than that observed in infected cells. No synergistic effect was seen with the combined 
treatment.  
To confirm the lysosomal dysfunction induced by HSV-1 and OS, the activity of  
β-hexosaminidase—another lysosomal hydrolase—was assessed. Consistent with the results 
obtained with CTSs, HSV-1 infection reduced its activity in a dose-dependent manner, just as X-
XOD treatment minimized its activity to a minimum (in mock and HSV-1 infected cells) (Figure 
14B). These results revealed severely altered proteolytic activity of lysosomes in HSV-1 infected 
and OS treated SK-N-MC cells. 
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For the microarray analysis, SK-N-MC cells were infected with a lower dose of HSV-1 
(moi of 0.1 pfu/cell for 24 and 36 hours) in the presence of a mild oxidative stress to mimic more 
likely the physiological conditions of natural infection. These analyses revealed that the main 
pathway altered was the lysosomal system. To confirm that the impairment of lysosomal function 
also takes place in cells treated at the same conditions as of microarray experiments, the amount 
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and functionality of lysosomes were determined. In these conditions, a marked increase of the 
lysosomal content—revealed by an increase of the LTR fluorescence (Figure 15A)—and a 
significant reduction of the activity of cathepsins B and D/E (Figure 15B) were observed in cells 
exposed to HSV-1 and OS both at 24 and 36 hours of treatment. 
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2.3. HSV-1 and OS alter endocytosis-mediated lysosomal degradation of the EGF 
receptor 
Potential alterations in lysosomal activity can also be measured monitoring the dynamics of 
the EGF receptor (EGFR). There are at least eight ligands of EGFR (Henriksen et al., 2013). Upon 
EGF binding, activated EGFR is rapidly internalized through endocytosis (Madshus et al., 2009). 
After internalization to early endosomes, ligand-receptor complexes are either kept in endosomes 
to mature into late endosomes and posterior degradation in lysosomes, or recycled back from early 
endosomes to the plasma membrane. This decision is partly determined by the ligand. EGF has 
been described to drive the receptor mainly toward degradation in lysosomes (Henriksen et al., 
2013) and is therefore used as a ligand in our experiments. Given the fact that SK-N-MC cells lack 
the endogenous EGFR (van Weering et al., 1995), SK-N-MC cells were transient transfected with 
an expression plasmid of EGFR tagged to cmyc (pEGFR-c-myc). In mock cells, the stimulation of 
EGFR degradation by EGF addition was not observed, the EGFR-c-myc protein levels stayed 
constant even after 5 hours of EGF treatment. However, HSV-1 infected cells showed an increasing 
level of EGFR over time (Figure 16A) suggesting a failure in EGFR degradation. Nevertheless, the 
lack of EGFR degradation in mock cells might be a consequence of the plasmid overexpression, 
and the experiments with SK-N-MC cells were not continued. Instead, we decided to use HeLa 
cells, which express endogenous EGFR, for the experiments regarding EGFR. 
To measure EGFR degradation, Western blot analyses using the anti-EGFR antibody were 
performed (Figure 16B). In mock cells, 1 hour after EGF stimulation, there was a decrease of 20% 
in the EGFR levels. After 3 hours, 75% reduction of EGFR was already observed which was 
maintained at 5 hours of EGF stimulation indicating the internalization and degradation of the 
receptor induced by EGF. In contrast, cells exposed to OS or HSV-1 infection showed an inhibition 
of EGFR degradation indicating an alteration of its lysosomal degradation by both treatments. In 
the absence of EGF, the amount of EGFR protein did not change at all time-points in either of the 
conditions (data not shown).  
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These results were confirmed by immunofluorescence experiments. In non-treated HeLa 
cells, EGFR was mainly localized to the plasma membrane and, after EGF addition, was 
internalized and rapidly degraded. In contrast, HSV-1 and OS induced a strong increase of EGFR 
intracellular staining (Figure 17), suggesting a defect of EGF-induced EGFR degradation caused by 
both treatments.  
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Given that EGFR is internalized by the endocytic machinery and then degraded by the 
lysosomes, tests were made to determine whether EGFR accumulation induced by HSV-1 and OS 
takes place in some compartment of this pathway. To do this, confocal microscopy analyses using 
antibodies specific to marker proteins of early endosomes (EEA1), late endosomes (insulin-like 
growth factor 2 receptor, CD222) and lysosomes (CD63) were performed. The distribution of 
EGFR was examined by 5 hours after EGF addition when the EGFR accumulation has already 
occurred (Figure 18). In non-treated cells, EGFR staining is not detected confirming the EGFR 
degradation. At 18 hpi no significant colocalization of EGFR with early endosomal or lysosomal 
markers was detected in all conditions tested showing that EGFR does not reach the lysosome. In 
contrast, confocal images revealed EGFR to colocalize significantly with CD222 in HSV-1 
infected cells indicating that HSV-1 caused the accumulation of EGFR in late endosomes. This 
colocalization was already observed at 16 hpi—3 hours after EGF addition. Interestingly, a change 
in the pattern of EGFR staining was observed in cells exposed to X-XOD indicating that OS 
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induced the EGFR accumulation in different cell compartments. To proof the specificity of the 
experiments, all time-points were also analysed in absence of EGF showing that without ligand the 
EGFR was not changing its location (data not shown). These findings indicate that the EGFR 
transport to the lysosomes was impaired in cells exposed to HSV-1 and OS confirming that both 
factors strongly impair the functionality of the lysosomal pathway. 
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2.4. HSV-1 infection and OS increase intracellular cholesterol levels 
A growing body of evidence suggest that alterations of cholesterol homeostasis could be 
implicated in the lysosomal dysfunction observed in the pathogenesis of AD (Chen et al., 2014). 
Our results also support this relationship because the candidate showing a positive association with 
the AD-group in the genetic association study (described in section 3.1)—LAMP2—has been 
directly associated with cholesterol. LAMP2 is localized to late endosomes/lysosomes and is 
thought to be implicated in cholesterol transport out of late endosomes/lysosomes to other cellular 
compartments (Schneede et al., 2011). 
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Unesterified cholesterol (also referred to as free cholesterol) is mainly localized to the 
plasma membrane (60-80% of the cholesterol in the cell), whereas cholesterol esters are packed 
into intracellular lipid particles and are mainly found in plasma. To address if HSV-1 infection and 
OS affect cholesterol levels in SK-N-MC cells, total unesterified cholesterol amount was quantified 
using the Amplex Red Kit. OS did not affect cellular cholesterol, however, HSV-1 infection 
provoked a significant increase of cholesterol levels (Figure 19A). The combination of both 
treatments led to an increase of cholesterol levels, though not significant. These results rule out that 
there is a synergic effect of HSV-1 infection and OS on cholesterol accumulation. 
Another popular method to visualize cellular cholesterol by fluorescence microscopy can 
be achieved with filipin staining. Filipin is a naturally fluorescent polyene antibiotic that binds to 
cholesterol but not to esterified sterols. Thus, we used this method to detect free (i.e., unesterified) 
cholesterol in our cell model (Figure 19B). In mock cells, almost all cholesterol is localized to the 
plasma membrane. Both conditions, HSV-1 infection and OS, provoked a strong accumulation of 
intracellular cholesterol. As a positive control, cells were treated with bafilomycin A1. This drug 
specifically inhibits the V-type H+-ATPase thereby blocking lysosomal acidification causing 
cholesterol accumulation in endo-lysosomal compartments (Furuchi et al., 1993). Interestingly, the 
staining pattern of the cells infected with HSV-1—in the presence or absence of X-XOD—was 
quite similar to that observed with Bafilomycin A1. Also the round shape of filipin positive 
structures remind of vesicles, suggesting that HSV-1 infection might induce the accumulation of 
cholesterol in endo-lysosomal compartments. 
As seen in Figure 19B, most cellular cholesterol locates to the plasma membrane. To focus 
on lysosomal cholesterol content, we first partially purified lysosomes from total cell lysates 
previous to measuring their cholesterol levels (Avrahami et al., 2013). As quality control of the 
purification, analysis of LAMP1 protein levels was monitored in the different fractions obtained 
during the process (Figure 19C). These results show that LAMP1 was mainly present in the 
fraction enriched in lysosomes (F4) and absent in the cytosolic fraction (F3) proofing the efficiency 
of this method. After purification of the lysosomes, these enriched lysates were analysed with the 
Amplex Red kit to measure the cholesterol levels. In consistence with the results obtained in total 
cholesterol levels, HSV-1 infection—in the presence or absence of X-XOD—caused an increment 
of the cholesterol amount in the fractions enriched with lysosomes (Figure 19D). These findings 
indicate that HSV-1 and to a lesser extent OS provoke an alteration of cholesterol homeostasis. 
Further experiments are required to test whether this alteration is responsible for lysosomal 
dysfunction induced by HSV-1 and OS.  
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In summary, using the human neuroblastoma cell line SK-N-MC, we observed that HSV-1 
infection and OS deeply alter the lysosomal pathway. Infection and OS lead to an increase of 
lysosomal burden, decreased activity of lysosomal enzymes, altered lysosomal degradation of the 
EGFR, and intracellular accumulation of cholesterol. All these findings suggest that our cell model 
of sporadic AD present severe perturbations of the lysosomal pathway and confirm the hypothesis 
that it might be a good therapeutic target for AD. 
3. Role of LAMP2 in the AD-like neurodegeneration events induced by HSV-1 and OS 
3.1. LAMP2 polymorphisms are associated with sporadic AD 
Microarray analysis of our cell models identified the lysosomal pathway as important 
player in the pathology of AD. To determine whether the candidates identified in our experimental 
models could be related to the real disease, potentially functional SNPs in six genes were selected 
(Table 8) and their association with sporadic AD investigated in case/control samples. The sample 
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was composed of 612 AD cases and 654 age-matched controls from northern and central areas of 
Spain as described in section 19 of Materials and Methods. The APOE genotype was analysed 
previously (Recuero et al., 2009; Rodriguez-Rodriguez et al., 2010). After the analysis of the 
individual SNPs in the whole sample, we looked for possible interactions with age, gender and 
APOE-ε4 genotype by sample stratification and in logistic regression models. We found no 
significant associations in the samples stratified (data not shown), except for LAMP2. Interestingly, 
we found that for this gene encoded on the X chromosome—especially in haplotype blocks 1 and 
2—there was a significant association with AD in males, with increased risk for APOE-ε4 carriers 
(Table 9). 
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Further studies will be performed to assess the genetic association of the genes of interest 
with SAD, including the analysis of epistatic effects (functional gene-gene interactions), like the 
one we found in the same sample between NPC1 and ATP-binding cassette transporter A1 
(ABCA1) (Rodriguez-Rodriguez et al., 2010). Therefore, we will further extend the sample size 
with additional samples in the context of the Spanish Consortium of Dementia Genetics 
(DEGESCO). In any case, our current data suggest that LAMP2, most probably integrated into 
“epistatic machineries”, could be a genetic risk factor for SAD. 
3.2. Generation of SK-N-MC cell lines with a stable knockdown for LAMP2 
After identifying LAMP2 in the genetic association study and the observation that LAMP2 
was strongly upregulated in the neuronal cell model of infection and OS, our next step was to 
generate a suitable cell model to study the role of LAMP2 in the lysosomal dysfunction and AD-
like neurodegeneration events induced by HSV-1 infection and OS. To achieve this, SK-N-MC 
cells were stably transfected with shRNAs specific for LAMP2. Five different shRNA clones  
(nos. 1-5) and one scrambled control plasmid (no. 6) were transfected individually and several 
LAMP2 knockdown cell lines were selected and expanded. Figure 20A shows Western blot 
analyses of LAMP1 and LAMP2 in these cell lines. In comparison with SK-N-MC cells, the 
LAMP2-deficient cell lines showed a clear reduction in LAMP2 protein levels (1-B1: 52%; 2-A4: 
76%, 5-A6: 60% reduction) without affecting the amount of the lysosomal protein LAMP1. The 
scrambled control-transfected cell line showed no decrease in LAMP2 (6-A2: 106%). Interestingly, 
the 5-A6 cell line also showed reduced LAMP1 protein levels (45% less) although the expression 
of this gene should not be affected by the knockdown of LAMP2.  
Determination of the relative LAMP2 mRNA levels of all LAMP2 isoforms by RT-qPCR 
confirmed the results obtained by Western blot (Figure 20B). Given that alternative splicing of 
LAMP2 generates 3 different isoforms and that their expression is tissue dependent, we additionally 
measured the expression of LAMP2B by using specific primers for this isoform. Both results were 
almost identical indicating the strong reduction of LAMP2 mRNA levels observed in these cell 
lines. In conclusion, the in-house generated LAMP2 knockdown cells are suitable for further 
studies about the involvement of LAMP2 in the events induced by HSV-1 and OS. 
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The group of P. Saftig in Germany generated LAMP2-deficient MEF and murine 
neuroblastoma N2a cells to study molecular mechanisms implicated in Danon disease, a X-linked 
disorder included in the LSDs caused by mutations in the LAMP2 gene and characterized by 
hypertrophic cardiomyopathy and mental retardation. MEF cells have a genetic knockout of the 
LAMP2 gene and the N2a cell line presents a stable knockdown of LAMP2 via shRNAs. For 
simplification, no differentiation between knockout and knockdown will be made in the text and it 
will be referred to both as “LAMP2-deficient cells”. These cell lines were kindly provided by 
Saftig’s laboratory to be included in this study.  
Before all else, LAMP2 mRNA and protein levels were analysed to verify the deficiency of 
LAMP2. Western blot experiments using a specific antibody for the murine LAMP2 confirmed the 
absence/reduction of LAMP2 in MEFs/N2a, respectively (Figure 21A). LAMP2-deficient N2a cells 
showed also a slight reduction of LAMP1 protein amount. Quantification of LAMP2 mRNA by 
RT-qPCR confirmed the results obtained by Western blot (Figure 21B). 
Considering that the remaining levels of LAMP2 protein in our deficient SK-N-MC cell 
lines were notably higher than those measured in deficient MEF and N2a cells and, consequently, 
differences between wt and LAMP2-deficient cells will be much more appreciable in these cell 
lines, we decided to perform the functional studies of the role of LAMP2 in MEF and N2a cells. 
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As a next step, the effects of LAMP2 expression on HSV-1 infection, lysosomal alterations 
and AD-like neurodegenerative markers induced by HSV-1 and OS were evaluated in these 
models. 
3.3. LAMP2 deficiency does not affect cell viability after X-XOD treatment 
The response to X-XOD treatment in SK-N-MC cells was extensively studied by our group 
(Recuero et al., 2009), e.g. it is known that 24 hours of treatment does not affect significantly cell 
viability. OS-induced apoptosis is known to appear upon 36-48 hours of X-XOD exposure. To 
determine whether the two murine cell lines—N2a and MEFs—behave the same way and secondly, 
if there is a differential response to X-XOD-induced mild OS in the presence/absence of LAMP2, 
the cell viability was determined using the MTT assay. No variations were observed in cell 
viability at 18 or 24 hours in none of the tested cell lines (Figure 22) indicating that LAMP2 has no 
effect on cell viability in the presence of OS. 
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3.4. LAMP2 deficiency decreases efficiency of HSV-1 infection 
As done for the X-XOD treatment, in the next experiments we first wanted to evaluate if 
the absence of LAMP2 affects HSV-1 infection. To do this, cells were infected with increasing 
viral dose (ranging from 0.1 to 10 pfu/cell) for 18 hours and viral protein levels were investigated. 
Western blot analyses showed an increase of the viral glycoprotein gC in a dose-dependent manner 
in wt and LAMP2-deficient cells. However, LAMP2 deficiency led to lower levels of gC compared 
to wt cells (Figure 23A and Figure 24A). The glycoprotein gC is a true late gene and the expression 
of this gene depends on viral DNA synthesis. The decrease in gC levels in LAMP2-deficient cells 
could therefore indicate altered viral replication and motivated us to further analyse viral DNA 
levels and the production of infectious particles. The quantification of viral DNA and extracellular 
infectious titer showed similar results for both cell lines (Figure 23B, C and Figure 24B), with less 
viral DNA and infectious particles in LAMP2-deficient cells. These results indicate that the 
absence of LAMP2 decreases the efficiency of HSV-1 infection. 
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Given that at a viral dose of moi 10 for 18 hours both cell lines, but especially MEF cells, 
seem to be severely affected (visual observations) and no large differences in the amount of viral 
protein and DNA were observed comparing moi 3 and moi 10 viral dose, the posterior experiments 
were performed at a moi of 3 pfu/cell. Immunofluorescence analysis confirmed that almost all cells 
were infected at this viral dose and time of infection (Figure 25). 
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Our group has previously reported that HSV-1 replication is severely compromised in  
SK-N-MC cells subjected to OS (Santana et al., 2013). In order to determine the effects of OS in 
LAMP2-deficient cell models, N2a cells were HSV-1 infected with different viral dose in the 
presence or absence of X-XOD and the amount of viral protein and DNA was quantified by 
Western blot and qPCR, respectively. Extracellular infectious particles were also determined by 
plaque assays. The combination of X-XOD and HSV-1 reproduced the results published from our 
group in SK-N-MC cells, showing that X-XOD decreases viral protein and DNA levels, as well as 
infectious titers in N2a cells. This inhibitory effect was also observed in the absence of LAMP2. In 
addition, lower viral protein and DNA levels were observed in LAMP2-deficient cells compared to 
wt (Figure 26). The reduction of viral gC levels induced by OS was also observed in MEF cells 
(Figure 27). These results indicate that, as occurs in SK-N-MC, OS is able to reduce HSV-1 
infection in N2a and MEF cells, independently of LAMP2 expression, and confirm the lower 
efficiency of infection in LAMP2-deficient cell lines. 
To evaluate if HSV-1 infection and OS affect LAMP2 expression, Western blot 
experiments of LAMP2 were also performed. These experiments confirmed again the 
absence/reduction of LAMP2 in the deficient cell lines. In N2a cells, HSV-1 decreased LAMP2 in 
a dose-dependent manner, whereas OS strongly increased LAMP2 protein levels (Figure 26). This 
effect was also observed in LAMP2-deficient cells. In contrast, in wt MEF cells, HSV-1 infection 
increased LAMP2 levels (Figure 27). OS also increased LAMP2—as observed in N2a cells—
independent of their infection status. These data are in agreement with the increase of expression of 
lysosomal genes induced by OS observed in the functional genomic analysis. 
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3.5. Effect of LAMP2 deficiency on lysosomal activity 
In the following block of results, MEF and N2a cells were analysed to assess whether the 
HSV-1-induced lysosomal dysfunction observed in SK-N-MC cells were reproduced in these 
murine cell lines, and secondly, the differential response of wt and LAMP2-deficient cells. 
In a first set of experiments, we evaluated the effect of HSV-1 and OS on lysosomal 
activity analysing the proteolytic activity of CTS D/E and β-hexosaminidase. As observed in SK-
N-MC cells, HSV-1 significantly decreased the proteolytic activity of β-hexosaminidase in N2a 
and MEF cells (Figure 28B). This trend was also observed when the activity of CTS D/E was 
measured (Figure 28A), but reached significance only in combination with X-XOD.  
RESULTS 
 
83 
 
OS strongly reduced the activity of CTS D/E in N2a and MEF cells (Figure 28A). However, unlike 
SK-N-MC, X-XOD treated MEF and N2a cells did not show reduced activity of β-hexosaminidase 
(Figure 28B). These OS and HSV-1-induced effects were observed likewise in wt and LAMP2-
deficient cells. 
When comparing the proteolytic activities of CTS D/E and β-hexosaminidase in HSV-1 
infected cells between wt and LAMP2-deficient cells, a general reduction of enzymatic activity in 
LAMP2-deficient N2a and MEF cells was observed, although no significance was reached or 
statistical analyses could not be performed yet (n=2). These data suggest that the HSV-1-induced 
decrease of lysosomal hydrolase activity is even more pronounced in LAMP2-deficient cells, even 
though more experiments are required to demonstrate this effect. 
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3.6. Effect of LAMP2 deficiency on AD-like neurodegeneration markers 
With the aim of assessing the role of LAMP2 in the appearance of neurodegeneration 
markers induced by HSV-1 and OS, the levels of tau phosphorylation, Aβ and LC3 were monitored 
in LAMP2-deficient MEF and N2a cells. 
3.6.1. Analysis of tau phosphorylation 
Western blot analyses were used to evaluate tau phosphorylation in the epitope thr205, 
which is known to be phosphorylated in AD brains (Goedert, 1993) and in HSV-1 (Zambrano et 
al., 2008) and HSV-2 infected cells (Kristen et al., 2015). The effects of LAMP2 deficiency on tau 
phosphorylation were also studied. A strong increase of tau phosphorylation was observed in  
HSV-1 infected N2a and MEF cells (Figure 29A and B), reproducing the results published by our 
laboratory in SK-N-MC cells (Alvarez et al., 2012). These results were confirmed by 
immunofluorescence analysis (Figure 30). In non-infected cells, almost no signal was seen. A week 
signal was only detected in mitotic cells, which is consistent with the fact that AD-like tau 
phosphorylation occurs during mitosis (Delobel et al., 2002). In contrast, HSV-1 infection strongly 
increased the levels of phosphorylated tau in the cells. No apparent differences were noted between 
wt and LAMP2-deficient cells. 
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3.6.2. Analysis of Aβ levels 
Firstly, immunofluorescence analysis was used to determine if HSV-1 infection and OS 
modify Aβ levels in wt and LAMP2-deficient N2a and MEF cells. As it has been described that 
most intraneuronal Aβ ends at residue 42 (Gouras et al., 2000; Takahashi et al., 2002), 
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immunofluorescence experiments using an antibody specific for Aβ42 were performed. No staining 
for Aβ42 was observed in mock or X-XOD treated cells. In contrast, accumulation of Aβ42 was 
observed in HSV-1 infected cells, a trend that seemed to be potentiated in combination with X-
XOD (Figure 31). No differences were apparent between wt and LAMP2-deficient cells. 
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We have reported that intracellular Aβ accumulation induced by HSV-1 in neuronal cells is 
partly mediated by decreased efficiency of the cells to secrete this peptide (Santana et al., 2012). 
Therefore, the levels of secreted Aβ40 and Aβ42 in conditioned media were measured by ELISA. 
As expected, HSV-1 caused a marked reduction in secreted Aβ40 and Aβ42 levels in N2a and 
reached undetectable levels in MEF cells (Figure 32). These results indicate that HSV-1 infection 
strongly reduces secretion of both Aβ peptides leading to intracellular accumulation of Aβ. Again, 
LAMP2 deficiency had no effect on the levels of secreted Aβ. 
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3.6.3. Analysis of LC3 levels 
Severe alterations of the autophagic pathway were observed in HSV-1 infected SK-N-MC 
cells (Santana et al., 2012). To test if HSV-1 interferes with autophagy in N2a and MEF cells, we 
analysed the autophagic marker LC3 by Western blotting. Upon the activation of autophagy, LC3 
is converted from its cytosolic form LC3-I to the autophagic membrane-bound form LC3-II. As 
shown in Figure 33, OS and HSV-1 infection strongly increased LC3-II levels in N2a and MEF 
cells suggesting an accumulation of autophagic vesicles in HSV-1 and OS treated cells, as occurred 
in SK-N-MC cells exposed to HSV-1 and OS (Santana et al., 2013). Similar results were observed 
in wt and LAMP2-deficient cells.  
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In summary, preliminary results in N2a and MEF cells showed that HSV-1 and OS induce 
the appearance of the main AD-like neurodegenerative markers including the increase of 
phosphorylated tau and LC3-II levels, accumulation of intracellular Aβ42, as well as reduced 
secretion of the Aβ peptides, therefore recapitulating the effects found in SK-N-MC cells. HSV-1 
and OS also caused a reduction of the activity of lysosomal hydrolases. So far, no differential 
response between wt and LAMP2-deficient cells was observed, except for the proteolytic activity 
of hydrolases. LAMP2-deficiency weakly accentuated the HSV-1-induced decrease in activity 
indicating a more severe lysosomal dysfunction in the absence of LAMP2. 
 
 
4. Generation of induced pluripotent stem cells 
The findings obtained so far result from work with cell models mimicking AD. The 
question is whether the molecular alterations observed are also present in the “real” disease. To 
overcome this gap, we proposed to study the lysosomal pathway in a more physiological model. 
Since the discovery of the Yamanaka factors and the fact that human/mouse somatic cells 
can be reprogrammed into pluripotent stem cells (iPSCs), this field has made great advances. 
Especially for multifactorial and sporadic diseases where a clear pattern of inheritance and good 
animal models are missing, this new technology is of great importance. Researchers worldwide 
have generated patient-specific iPSC lines to gain insight into disease mechanisms and have used 
them for drug screening, identification of biomarkers and clinical trials of personalized therapies.  
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The experimental set-up is quite complicated and lengthy and there are still many 
unanswered questions to fully understand reprogramming and pluripotency, but mainly the protocol 
efficiency has to be improved (reviewed in depth in Li et al., 2016). The “iPS” segment of the 
present thesis is subdivided into four parts: 
I. Generation of primary culture of fibroblasts derived from one AD patient and 
control. 
II. Reprogramming of fibroblasts into iPSCs. 
III. Characterization. 
IV. Differentiation of iPSCs into neurons. 
Finally, the generated iPSCs/differentiated neurons will then be analysed to confirm the 
alterations of the lysosomal pathway observed in SK-N-MC, N2a and MEF cells. They will also be 
used to study if there is a differential behaviour in response to HSV-1 infection and/or OS in 
neurons derived from AD patients and control individuals. 
In this study we used samples from two individuals that were selected from a group of 
volunteers participating in a longitudinal study (ELMO: Longitudinal Multicentric Observational 
Study) about AD in collaboration with Dra. Ana Frank of the Hospital Universitario La Paz. One 
was classified as sporadic AD patient that, at the moment of sample removal, presented clinical 
features of a person with mild cognitive impairment (herein referred to as patient [P]) and the 
second individual was an age-matched control (C). 
In the following sections the results obtained so far concerning part I. to III. will be 
described: 
4.1. Establishing primary cell cultures from patient biopsies 
iPSCs can be generated from diverse adult somatic cells. The less invasive option for the 
donors is the use of dermal fibroblasts as starting material. In our case, these fibroblasts were 
obtained by the processing of a skin punch biopsy of the individuals. Therefore, a 6 mm skin 
specimen was extracted from their forearms. These skin samples were then cut into smaller pieces 
and attached to the bottom of a cell culture flask (Figure 34; Day 0). After a few days, outgrowth of 
keratinocytes surrounding the attached biopsy was noticed. 10 days post-biopsy the outgrowth of 
early fibroblasts was observed in both samples. By 18 days a dense monolayer of fibroblasts (HDF) 
was observed and cells were passaged into bigger flasks for expansion. Only a small amount of 
cells was required for the following reprogramming experiment, so the rest was frozen down. No 
apparent differences of cell morphology (shape and size) and cell proliferation between patient and 
control fibroblasts were observed (Figure 34). 
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4.2. Generation of iPSCs  
The generated fibroblasts were then used to be reprogrammed into iPSCs using integration-
free CytoTune®-iPS 2.0 Sendai Reprogramming Kit that includes Sendai virus particles of the four 
Yamanaka factors (OCT3/4, SOX2, KLF4, and c-MYC). Figure 35A shows the timeline respected 
during this reprogramming experiment. On day 0, HDFs were transduced with the four Yamanaka 
factors. After 7 days, cells were replated onto a monolayer of irradiated MEFs. By 12 days, the first 
clumps were spotted and by 18 days, colonies with iPSC morphology were observed in both 
preparations (Figure 35B). Several iPSC lines were generated from individual colonies. Some 
colonies did not grow after the first round of mechanical passaging. From those who did expand, 
two patient-derived (called P-I and P-II) and two control-derived cell lines (C-I and C-II) were 
selected for further maintenance and analysis.  
iPSC colonies have a very characteristic phenotype. Recent studies reported the quality 
evaluation of iPSCs by their colony morphologies (Scherf et al., 2012; Suga et al., 2015; Tokunaga 
et al., 2014). Figure 36 shows representative images of the grown colonies. They showed the 
expected sharp edges and the dense packaging of cells inside the colonies (Robinton et al., 2012; 
Wakao et al., 2012). The four cell lines were mechanically passaged every other week for 
expansion and characterization. 
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5. Characterization of iPSC lines
It is of great importance to characterize exhaustively the developed iPSC lines in order to 
demonstrate their pluripotency. The International Stem Cell Banking Initiative (ISCBI) (Crook et 
al., 2010) recommends several tests, which has served us as guideline.  
5.1. Alkaline phosphatase and TRA1-60 staining 
Alkaline phosphatase (AP) staining is normally the first assay to perform. The AP enzyme 
is able to change the conformation of a colorimetric reagent from a soluble to a precipitated state. A
clear blue signal in the colonies and no staining of the feeder cells should be observed. In Figure 
37A microscope images of an individual iPSC colony are shown before and after staining with AP. 
The colony revealed a partial positive staining, but the border of the colony seemed to be less 
intense. To clarify whether our iPSC cell lines were pluripotent, they were live stained with an 
antibody specific for TRA1-60—one of the fastest and most reliable methods for identifying a 
reprogrammed colony. Figure 37B shows that all cells of the colonies are TRA1-60 positive, 
whereas the cells from the surrounding feeder layer were clearly negative. In conclusion, all four 
established iPSC lines are positive for TRA1-60 indicating their pluripotent state. 
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After several weeks of passaging, the two control cell lines started to differentiate. Inside 
the colonies the appearance of other cell types were noticed (Figure 38; marked with asterisk). To 
confirm that the colonies did lose their undifferentiated/pluripotent state, TRA1-60 live staining 
was performed again. Unlike the staining pattern seen in recent reprogrammed colonies (Figure 
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37B), those colonies now represented a heterogeneous staining with mainly negative cells 
confirming the differentiation of these colonies. Both control cell lines were affected by these 
differentiation events and were therefore discarded. The following characterization experiments 
were performed consequently only with the two iPSC lines generated from the AD patient. 
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5.2. Analysis of the expression of pluripotency markers in iPSC lines  
Once TRA1-60 positive colonies are determined, the next step is to confirm their 
pluripotency by immunostaining. A set of biochemical and molecular markers has been identified 
that are specific for iPSCs and fundamental to maintaining the undifferentiated state (Ohnuki et al., 
2009). Immunofluorescence analysis of the two remaining cell lines (P-I and P-II) revealed 
expression of nuclear transcription factors OCT4, NANOG, SOX2; keratin sulphate surface 
antigens TRA1-60 and TRA1-81; and glycolipid antigens SSEA3 and SSEA4 (Figure 39A and B).  
In addition, quantitative RT-PCR analysis also demonstrated high levels of expression of 
the pluripotency markers including OCT4, SOX2, REX1, NANOG and CRIPTO (Figure 39C). 
Additionally, expression levels of differentiation markers for the three germ layers were analysed. 
Only PAX6—an early differentiation marker for ectoderm—showed a slight increase in both iPSC 
lines compared to fibroblasts. The other ectodermal marker (TUBB3), and the early differentiation 
markers for mesoderm (HNF4), endoderm (SOX17, FOXA2) or cardiomyocytes (MEF2C, TBX5) 
showed no expression in the iPSC lines.  
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To finish their characterization, the following experiments need to be performed:  
(i) Bisulfite pyrosequencing of the OCT4 and NANOG promoters for the determination of 
their methylation states. Promoters of pluripotency-associated genes are methylated in the original 
fibroblasts but almost completely demethylated in iPSC lines. 
(ii) Karyotype analysis for the evaluation of genomic integrity. 
(iii) Differentiation tests to demonstrate that the generated iPSCs can differentiate into the 
three germ layers of the embryo (endoderm, mesoderm and ectoderm). This can be shown via in 
vitro (via the formation of embryoid bodies) or in vivo (teratoma formation) tests. 
(iv) DNA fingerprinting analysis for the verification that the iPSC lines are genetically 
matched to the donor cells. 
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1. Identification of the lysosomal pathway as involved in SAD 
Oxidative stress and HSV-1 infection play critical roles in the pathogenesis of AD (Harris 
et al., 2015; Persson et al., 2014; Tonnies et al., 2017). In addition, other members of the 
herpesvirus family have been associated to AD—HSV-2, HHV6 and CMV (Harris et al., 2015; 
Kristen et al., 2015; Lin et al., 2002). Over the last years, our group has contributed to the growing 
number of experimental evidence supporting the damaging relationship of both factors. To study 
the molecular mechanisms involved in AD, we developed a neuronal cell model of mild OS and 
HSV-1 infection. We showed that HSV-1 induces the main AD-like neurodegenerative events, 
such as aberrant tau phosphorylation (Alvarez et al., 2012), autophagy impairment (Santana et al., 
2012), altered trafficking and metabolism of APP protein and the accumulation of the β-amyloid 
peptide (Santana et al., 2012). We also showed that mild OS—induced by the X-XOD system—
activates cholesterol synthesis (Recuero et al., 2009) and alters autophagy/lysosome system 
(Recuero et al., 2013). Finally, OS is able to enhance the neurodegenerative events associated with 
HSV-1 infection (Santana et al., 2013).  
To identify genes and pathways altered by HSV-1 infection and OS that might be 
implicated in AD, microarray analyses were performed to profile global changes in gene expression 
modulated by HSV-1 and OS. The main objective of the present thesis was to identify genetic risk 
factors common for the sporadic and familial forms of the disease. Although the underlying causes 
for both forms are different, the clinical and pathological manifestations are very similar. They 
share the two pathological hallmarks of the disease—NFTs and SPs—and it is widely thought that 
both forms have similar molecular mechanisms. To generate a cell model of FAD (herein referred 
to as monogenic model), our laboratory developed a cell line, based on SK-N-MC cells, expressing 
human APP695 harbouring the Swedish mutation (APPswe). We then compared the list of OS-
modulated genes in our infection model with those obtained in our monogenic model and focused 
on the overlap between the two datasets. By doing so, a list of 68 genes was obtained. Although 
two time points (24 and 36 hpi) were prepared for analysis by microarrays, we focused on 24 hpi 
because this is the first time point at which expression is modulated in a significant number of 
genes and functional changes are just initiated (previous laboratory data). Since large amount of 
data were generated by such microarrays, bioinformatics tools were used to further analyse the lists 
of differentially expressed genes. These tools use statistical analyses to identify categories (like 
biological processes or functions) that are over- or underrepresented in a given condition. These 
data mining techniques revealed significant annotations to the lysosomal pathway (identified by 
two independent analyses, GeneCodis and IPA) and to a lesser extent to the metabolism of sterols 
(only with IPA). The five genes from our dataset that form part of the lysosomal pathway are 
involved in different aspects of this pathway: (i) ATP6AP1 encodes for a component of the V-
ATPase, though plays a role in V-ATPase-mediated acidification of acidic organelles. (ii) CTSF is 
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a member of the papain family of cysteine proteinases and is a component of the lysosomal 
proteolytic system. (iii) LAMP2 is one of the major lysosome-associated membrane proteins 
important for the protection, maintenance and adhesion of the lysosome. (iv) LIPA encodes a 
lysosomal acid lipase that catalyses the hydrolysis of cholesteryl esters and triglycerides. (v) NPC1 
is primarily located to lysosomes and endosomes, and mediates intracellular cholesterol trafficking. 
Our findings are supported by several GWAS studies identifying polymorphisms associated with 
AD involved in endocytosis and lipid metabolism (Harold et al., 2009; Jones et al., 2010; Lambert 
et al., 2009) (Figure 2). Among them, PICALM, SORL1, CD2-associated protein (CD2AP), and 
bridging integrator 1 (BIN1) are those involved in endocytosis and APOE, SORL1, CLU, and 
ABCA7, are involved in lipid metabolism. How exactly they contribute to neurodegeneration is 
under intense investigation, but it has been already shown that some of these variations result in 
abnormal trafficking in the endo-lysosomal and autophagic networks (Cormont et al., 2003; 
Moreau et al., 2014). Interestingly, several of them—namely APOE, ABCA7, CD2AP, and 
PICALM—have been associated directly or indirectly with the herpes simplex life cycle supporting 
the implication of HSV-1 in AD pathogenesis (Licastro et al., 2011; Porcellini et al., 2010). The 
authors suggest that these genes (among others) cause a genetic signature that might affect the 
individual CNS ability to cope with and fight against invasion of herpesviruses. All these evidence 
from GWAS are in concordance with and confirm our results obtained from cellular models of AD, 
not only pointing to the lysosomal system as relevant pathway but also strengthen the hypothesis of 
a causal role for HSV-1 in AD. This concordance shows nicely that basic research based on cell 
models is adequate to study molecular mechanisms involved in complex diseases.  
The link between lysosome dysfunction and neurodegeneration has been evidenced by 
numerous research groups and is still under intense investigation because of its great potential as 
pharmacological target (Appelqvist et al., 2013; Whyte et al., 2017). Neurons are especially 
vulnerable to lysosome dysfunction and rely deeply on functional autophagic and endocytic 
pathways because these postmitotic cells are otherwise unable to dilute debris and undigested 
material through cellular divisions. Their size and polarity add further difficulties since very long 
neurites force the cellular machinery to manage the transport of material to mature lysosomes over 
long distances (Neefjes et al., 2014). Abnormalities of the lysosomal system in AD include very 
early-appearing endosome enlargement, accumulation of autophagic vesicles, increased lysosome 
biogenesis and lysosomal proteolysis deficits (Nixon et al., 2011). Insights in disease-causing 
mechanisms associated to lysosomal failure came from observations in cell models for FAD. 
PSENs have been intensively studied because of their proteolytic action on APP within the γ-
secretase complex. Additional γ-secretase-independent functions have been reported, including 
cellular signalling, intracellular calcium homeostasis, endo-lysosomal trafficking and autophagy 
(reviewed in Peric et al., 2015). PSEN-deficient cells show accumulation of autophagic vesicles 
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and multivesicular bodies (MVBs) (Dobrowolski et al., 2012), as well as defects in lysosomal 
acidification and degradation. These defects cumber the degradation of Aβ thereby favouring AD 
pathogenesis (Lee et al., 2010). Other authors reported compromised lysosomal calcium storage 
and release in PSEN-deficient cells and neurons causing lysosomal dysfunction (Coen et al., 2012). 
Taken together, these data support the role of the lysosomal pathway in FAD.  
Lysosomal storage diseases (LSDs) are a group of disorders that are caused by dysfunction 
of lysosomal hydrolases or in a lesser extent by defective lysosomal membrane proteins (Filocamo 
et al., 2011). This leads to the accumulation of undigested material in compartments of the 
autophagic and endocytic machinery, along with the accumulation of autophagic and endocytic 
compartments themselves, resulting in the appearance of neurodegenerative phenotypes (Nixon et 
al., 2008). These abnormalities have also been reported in AD models and in our cell model of 
HSV-1 infection and OS, highlighting the implication of the lysosomal system in CNS pathologies 
and supporting the hypothesis that lysosomal dysfunction can cause the neurodegeneration induced 
by HSV-1 and OS. 
2. Alterations of lysosomal function induced by HSV-1 and OS 
To confirm the data of the functional genomic analysis indicating that the lysosomal 
pathway could be affected in our neuronal cell model, we studied different aspects of this pathway 
in depth. We first analysed the effect of HSV-1 and OS on the amount of lysosomal proteins. Our 
experiments showed that HSV-1 infection and OS increased the amount of the endo-lysosomal 
proteins Rab7, LAMP1 and LAMP2, suggesting increased lysosomal burden in these cells. In this 
respect, increased levels of these proteins were found in the cerebrospinal fluid (CSF) of AD 
patients (Armstrong et al., 2014), and Rab7 and LAMP1 have been previously reported to be 
upregulated in the AD brain (Barrachina et al., 2006; Ginsberg et al., 2010).  
Another more quantitative method to measure lysosomal content is the use of 
lysosomotropic dyes. Two different ones were used—LysoSensor Green (LSG) and LysoTracker 
Red (LTR). The LSG fluorescence is pH-sensitive and can indicate not only changes in number but 
also in lysosomal pH. The maximum of LSG fluorescence is obtained close to the lysosomal pH. In 
contrast, LTR accumulates in cellular compartments with low internal pH but exhibits fluorescence 
largely independent of pH. HSV-1 infection increased the fluorescence intensity of both dyes 
confirming the increase of lysosomal burden induced by the infection. Accumulation of lysosomes 
is a well known hallmark of AD brains (Gowrishankar et al., 2015). OS only showed enhanced 
fluorescence of LTR, but had no effect on LSG fluorescence. These differences might be explained 
by the fact that OS is known to cause lysosomal membrane permeabilization, thereby releasing 
hydrolases from the lysosomal lumen into the cytosol and causing the alkalization of lysosomes 
(Johansson et al., 2010). In this context, a recent report showed that sub-lethal oxidative stress is 
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able to induce lysosome biogenesis and lysosomal membrane permeabilization in rat myoblasts 
(Leow et al., 2017). A possible scenario might be that X-XOD, which also induces a sub-lethal 
oxidative stress in our cell models, provokes an increase of lysosomal burden but at the same time 
increases lysosomal pH through the induction of lysosomal membrane permeabilization. Taken 
together, these results indicate that HSV-1 infection and OS increase lysosomal content. This could 
be either due to increased induction of lysosome biosynthesis or due to defective lysosomal 
clearance or a combination of both.  
Given the increased number of lysosomes caused by HSV-1 and OS, we then focused on 
the effect of both stimuli on lysosomal proteolytic activity. The lysosome contains over 50 different 
hydrolases with particular importance of proteases. We found that HSV-1 infection significantly 
decreased activity of all analysed cathepsins (CTS B, K, S, and D/E). OS itself strongly reduced 
their activity as described previously by Porter et al. (2013). They observed decreased activities of 
serine, cysteine, and aspartyl protease activities, and defective cathepsin B maturation in trabecular 
meshwork cells (Porter et al., 2013). Numerous examples showing inhibition of lysosomal 
enzymatic activity by OS have been reported. Importantly, mutations in CTS D cause neuronal 
ceroid lipofuscinosis (NCL)—a human LSD with severe mental retardation and dementia, and CTS 
F and D deficiency in mice lead to a phenotype that resembles NCL (Koike et al., 2000; Tang et 
al., 2006). In addition, inhibition and/or loss of the cathepsins B and L lead to lysosomal 
dysfunction and accumulation of intracellular cholesterol and Aβ (Cermak et al., 2016). These 
findings indicate the importance of cathepsin activity for maintaining lysosomal function and 
preventing neurodegenerative processes.  
The activity of the lysosomal hydrolase β-hexosaminidase is also reduced by HSV-1 
infection and strongly inhibited by OS. In contrast, increased β-hexosaminidase activity was 
measured in skin fibroblasts from AD patients, presymptomatic individuals with FAD mutations 
(Emiliani et al., 2003; Pitto et al., 2005) and in the cortex of a murine model of FAD (Magini et al., 
2015). However, there are several reports in line with our findings describing decreased activity of 
lysosomal enzymes in association with AD (recently reviewed in Whyte et al., 2017). Lysosomal 
hydrolases are synthesized as inactive precursors and activated during transport through endosomes 
to lysosomes by acidification and proteolysis (Repnik et al., 2012). HSV-1 and OS might affect 
their maturation, maybe due to interference with other proteases required for proteolytic cleavage. 
In agreement with this hypothesis, an alteration of endosomal trafficking mediated by the 
glycoprotein B of HSV-1 has recently been reported (Niazy et al., 2017). The analysis of cathepsins 
by Western blot using antibodies that recognize immature precursors and mature forms of the 
protein could help to elucidate if alterations in cathepsins maturation could be the case in our 
infection cell model. The activation of endogenous inhibitors of cathepsins could be another 
mechanism causing the reduction in their activity. To evaluate this option, we could measure if the 
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levels of natural cathepsin inhibitors—like cystatins—are modulated by HSV-1 and OS in our cell 
model. In conclusion, HSV-1 and OS were found to induce an increase of lysosomal burden that 
did not correlate with an increase of lysosome enzyme activity. By contrast, HSV-1 and OS 
severely impair the proteolytic activity of lysosomes. 
Considering the significant decrease in lysosomal enzyme activities, enhancing lysosome 
efficiency might be a possible therapeutic strategy in AD. Genetic depletion of cystatin B—the 
natural inhibitor of cysteine proteases—rescues autophagic/lysosomal dysfunction and attenuates 
amyloidogenesis and related memory and cognitive deficits in an AD mouse model (Yang et al., 
2011; Yang et al., 2014). Improvement of synaptic function has been described in APP transgenic 
mice by deletion of cystatin C—the endogenous inhibitor of cysteine proteases like CTS B—(Sun 
et al., 2008), overexpression of CTS B (Mueller-Steiner et al., 2006) or pharmacological 
stimulation of cysteine protease activities (Butler et al., 2011). These strategies are already under 
investigation in research and clinical trials for the treatment of several LSDs showing promising 
results (Schultz et al., 2011) and could be of great interest for the treatment of AD. In concordance, 
modulation of the transcription factor EB (TFEB) function—the master regulator of lysosomal 
biogenesis—has recently been suggested to be neuroprotective in different studies. Overexpression 
of TFEB reduced NFT pathology and rescued behavioural and synaptic deficits and 
neurodegeneration in mice (Polito et al., 2014) and promoted the clearance of intracellular Aβ42 in 
SH-SY5Y cells (Xiao et al., 2015). These studies support the implication of lysosomal dysfunction 
in neurodegeneration. We have already started to test the effects of TFEB overexpression in our 
SAD cell model. Preliminary results showed that HSV-1 infection enhanced the TFEB gene 
expression and affected the cellular distribution of TFEB provoking its translocation to the 
nucleus—a sign of TFEB activation (unpublished data from our laboratory). These data suggest 
that HSV-1 could increase lysosome biogenesis through the activation of TFEB pathway. 
Defects in the endocytic pathway have also been associated with lysosomal dysfunction 
and were evaluated in our cell model. Moreover, impairment of this pathway is one of the earliest 
observations in AD (Peric et al., 2015). A popular method to analyse the endocytic pathway is to 
monitor the degradation of the EGF receptor (EGFR) upon stimulation by its ligand. After 
activation by EGF, the receptor-ligand complex is internalized and sent to endosomes. From there 
the complex reaches the lysosome for degradation, and the receptor is recycled back to the plasma 
membrane (Madshus et al., 2009). With the aim of studying the EGF-induced EGFR degradation in 
our cell model of infection, SK-N-MC cells were transfected with a pEGFR-c-myc expression 
plasmid due to the lack of expression of endogenous EGFR in SK-N-MC cells. In untreated cells, 
upon EGF stimulation, no differences in the EGFR levels were found. However, in HSV-1 infected 
cells, there was a strong accumulation of EGFR indicating a defect in EGFR degradation. The fact 
that no differences in the EGFR levels were observed in untreated cells could be related to EGFR 
DISCUSSION 
 
 
104 
 
overexpression. In fact, ligand-induced EGFR degradation has a low capacity and the pathway is 
easily saturated (Lund et al., 1990; Wiley, 1988). The experiments regarding EGFR were therefore 
performed in another well known model by our group—HeLa cells. This cell line expresses EGFR 
and numerous reports of EGFR internalization and degradation have been published. Our results 
with HeLa cells showed that OS and HSV-1 strongly inhibit EGFR degradation stimulated by EGF, 
indicating that under those conditions lysosomal degradation was impaired. This might be 
explained by HSV-1 and OS-induced defects in endocytic trafficking. In this sense, overexpression 
of HSV-1 glycoprotein B cause an impairment of the endosomal trafficking (Niazy et al., 2017). To 
measure if the EGFR reaches the lysosome, confocal microscopy experiments were performed. The 
results revealed colocalization of EGFR with late endosomes in HSV-1 infected cells suggesting 
that the final step of this pathway—probably the fusion of late endosomes with lysosomes—is 
altered. The fusion of lysosomes with autophagosomes is also deeply altered in HSV-1 infected 
cells (Santana et al., 2012) indicating that both pathways converging in the lysosome are not able to 
deliver cargo to the lysosome causing accumulation of autophagosomes and endosomes in our 
infection model. This hypothesis is supported by a study from Coen et al. (2012). They observed 
defective endosome-lysosome fusion in PSEN-deficient cells. In their view, altered lysosomal 
calcium storage and release is the primary cause of these fusion defects that subsequently cause 
endosome accumulation. It would be interesting to explore alterations in lysosomal calcium in our 
cell model to evaluate if HSV-1 and OS affect calcium homeostasis. Considering that APP and 
APOE—two important players in AD etiology—are localized in endocytic compartments, it is not 
surprising that the observed fusion defects might contribute to neurodegeneration. Accordingly, 
endosomal alterations have been observed in pyramidal neurons of AD patients (Cataldo et al., 
1997). They observed accumulation of enlarged endosomes and altered trafficking of hydrolase-
containing endosomes leading to accelerated β-amyloidogenesis. In conclusion, the lysosomal 
alterations found in our cell model, like increased lysosomal burden, decreased activity of several 
lysosomal hydrolases and defective endocytosis-mediated EGFR degradation provoked by HSV-1 
and OS, validate our results obtained from the functional genomic analysis pointing to the 
lysosome as the main altered pathway. In addition, these alterations induced by HSV-1 and OS 
might contribute to neurodegeneration by increasing Aβ production and tau phosphorylation and 
decreasing degradation of toxic aggregates. 
The second pathway enriched in our data set from microarray analysis was the metabolism 
of sterols. Previous data from our group showed that OS induces cholesterol biosynthesis and that 
polymorphisms in HMGCR—the rate-limiting enzyme for cholesterol synthesis—are associated 
with AD risk (Recuero et al., 2009). Cholesterol is the major source of sterols in mammals and 
numerous studies suggest that cholesterol homeostasis alterations could be causing the lysosomal 
dysfunction observed early in neurodegeneration, in particular in AD (Chen et al., 2014). In diverse 
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LSDs, cholesterol accumulates in endo-lysosomal membranes affecting either the lysosome ability 
to fuse with endocytic or autophagic vesicles, maturation of autophagosomes or lysosomal 
proteolysis (Fraldi et al., 2010; Maetzel et al., 2014). All these evidence links cholesterol 
homeostasis and lysosomal dysfunction motivating us to investigate whether changes in lysosomal 
cholesterol levels could be causing the lysosomal defects in our cell models.  
To evaluate cholesterol levels in our cell models two different methods were applied. First, 
a quantitative enzymatic assay measuring cellular unesterified cholesterol and second, filipin 
staining to visualise free cholesterol by fluorescence microscopy. Our results show that HSV-1 
infection caused a significant increase of cholesterol levels, a trend that was not potentiated by the 
addition of OS. On the other hand, OS alone did not modify significantly the amount of cellular 
cholesterol. In addition, filipin experiments revealed the accumulation of cholesterol in intracellular 
compartments in cells exposed to HSV-1 and OS. These data suggest that HSV-1 infection affects 
cholesterol homeostasis more than OS does. To date, there are few reports linking herpes virus 
infections with alterations of cholesterol homeostasis. HSV-1 infection impaired the cholesterol 
metabolism of human arterial smooth muscle cells producing accumulation of cholesteryl esters 
(Hajjar et al., 1987). Accordingly, another study reported altered cholesterol trafficking in HSV-1 
infected arterial smooth muscle cells (Hsu et al., 1995). 
Filipin staining indicated that in untreated control cells most of the cell free cholesterol is 
located to the plasma membrane. In contrast, HSV-1 and OS treated cells showed a filipin staining 
pattern similar to that seen in Bafilomycin A1 treated cells. Bafilomycin A1 specifically inhibits 
the V-ATPase thereby blocking lysosomal acidification causing cholesterol accumulation in endo-
lysosomal compartments (Furuchi et al., 1993). These results suggest that HSV-1 and OS cause 
cholesterol accumulation in compartments of the endo-lysosomal pathway. To further verify this 
hypothesis, double labelling of cells with filipin and diverse markers specific for compartments of 
this pathway will be done. All these evidence drove us to focus on lysosomal cholesterol levels in 
our cell model. Furthermore, the fact that cellular cholesterol is mainly located to the plasma 
membrane could disguise small changes in lysosomal cholesterol levels. Therefore we adapted a 
protocol for the partial purification of lysosomes. Analysis of the fraction enriched in lysosomal 
membranes showed increased cholesterol after HSV-1 infection. These results are in concordance 
with those obtained for total cholesterol levels, although the HSV-1-induced increase of lysosomal 
cholesterol is higher than of total cholesterol amount (166% and 116%, respectively). In this sense, 
cholesterol and other lipids accumulate in several LSDs and have been proposed to be causative for 
lysosomal dysfunction (Sobo et al., 2007; Walkley et al., 2009) and impairment of endocytic 
pathways (Rappaport et al., 2016). In two severe neurodegenerative LSDs—multiple sulphatase 
deficiency and mucopolysaccharidosis type IIIA—the accumulation of cholesterol alters the 
organisation of endo-lysosomal membranes affecting the fusion of lysosomes with endosomes and 
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with autophagic vesicles (Fraldi et al., 2010). These autophagic defects have also been reported in 
our infection cell model (Santana et al., 2012) supporting an active role of cholesterol accumulation 
in the vesicular fusion defects induced by HSV-1 and OS. Also, in Niemann-Pick disease C1 
(NPC1) the primary accumulation of sphingosine causes altered calcium homeostasis, what in turn 
causes the secondary accumulation of sphingolipids and cholesterol inhibiting the endocytic 
pathway (Lloyd-Evans et al., 2008). In conclusion, our data support the hypothesis that altered 
cholesterol homeostasis could be one of the mechanisms causing the lysosomal dysfunction 
induced by HSV-1 infection and OS. 
High levels of neuronal cholesterol have been linked to the appearance of AD-like 
neurodegeneration markers (Djelti et al., 2015; Xue-shan et al., 2016). Pharmacological modulation 
of cholesterol might therefore be a therapeutic target for the neurodegenerative events produced by 
HSV-1 and OS. Indeed, administration of the cholesterol-lowering drug 2-hydroxypropyl-beta-
cyclodextrin (HP-β-cyclodextrin) is proposed as potential therapeutic tool in NPC1 and AD (Aqul 
et al., 2011; Yao et al., 2012). The neuroprotective effects of HP-β-cyclodextrin are mediated by 
reduced Aβ production and enhanced clearance mechanisms (Yao et al., 2012). Lovastatin—an 
inhibitor of cholesterol synthesis—also suppressed the aberrant tau phosphorylation induced by 
okadaic acid and FTDP-17 mutations in cultured rat primary neurons (Li et al., 2015). To test the 
hypothesis that cholesterol depletion might attenuate lysosomal impairment and the 
neurodegenerative events induced by HSV-1 and OS, the modulation of cholesterol levels in our 
cell models is required. Reduction of cholesterol levels will be accomplished with methyl-β-
cyclodextrin (MβCD; a cholesterol-binding agent) or lovastatin and increased lysosomal 
cholesterol will be reached with U18666A (an inhibitor of endo-lysosomal cholesterol export). The 
optimisation of these agents in our cell models has already been initiated. 
3. Role of LAMP2 in AD-like neurodegeneration induced by HSV-1 and OS 
So far, the results obtained in this thesis are drawn from in vitro experiments with cell 
models mimicking SAD. In this way, microarray analyses pointed to the lysosomal pathway as 
important player in the neurodegenerative events in our infection cell model and identified a list of 
putative candidates that might mediate the HSV-1 and OS-induced damage. Here, LAMP2 was 
among the most strongly modulated ones. An important question is whether the candidates 
discovered in the cell models are involved in the “real” disease. The access of our group to 
case/control samples helped us to confirm some in vitro results with actual data from AD patients. 
Genetic association studies suggested the implication of LAMP2 in SAD confirming the 
validity/outcome of our cell model experiments. Our results showed significant association for 
LAMP2 with males, with increased risk for APOE-ε4 carriers. These results will be replicated in an 
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additional sample of 10,000 cases/controls, available through our association to Dementia Genetics 
Spanish Consortium (DEGESCO).  
These findings are interesting because they point to a potential molecular mechanism 
involved in the consistently reported gender difference on genetic susceptibility to AD. Since 
LAMP2 is located on the X chromosome, it is tempting to speculate that the preferential association 
in men that we observe could be attributed to the fact that males are “hemizygous” for LAMP2. In 
this sense, a recent study reported the role of autophagy in some paradigmatic human diseases 
(cancer, neurodegenerative, autoimmune, cardiovascular) and the presence of ‘cell sex’ differences. 
In this review they provided evidence that the involvement of the autophagic pathway in 
neurodegenerative diseases is gender-dependent (Lista et al., 2011). Further, a study on neuronal 
cells exposed to nutrient starvation showed that neurons from males more readily undergo 
autophagy and die, whereas neurons from females mobilize fatty acids, accumulate triglycerides, 
form lipid droplets and survive longer, and suggested that autophagic response could be gender and 
tissue specific (Du et al., 2009). Although more data are needed to confirm our current genetic 
association results, the study of the molecular basis of gender differences in AD prevalence and 
clinical expression is undoubtedly of great interest since not only the prevalence (Genin et al., 
2011), but also the clinical and neuropathological manifestations (Gallart-Palau et al., 2016; Lin et 
al., 2015) and response to treatments differ between men and women. The effect of gender on AD 
susceptibility is especially intriguing in the context of our project considering that HSV-1, like AD, 
appears to have a preference for the female gender (reviewed in Itzhaki, 2014).  
To strengthen the hypothesis for a causal role of HSV-1, it would be of great value to know 
whether the study subjects have HSV-1 in their brains, especially in combination with their genetic 
background like LAMP2 and APOE genotype. However, this observation can only be performed 
post-mortem, since there are no available tools for in vivo detection of the virus in the brain. 
Moreover, the mere presence of the virus would not demonstrate its pathogenicity, and several 
factors must be taken into account to determine it: the brain area where the virus is located, the 
state of infection (latent or lytic), the strain and genotype of the virus and the genotype of the host. 
In summary, proving a causal role for HSV-1 is a hard task, as occurs for virtually all the infectious 
agents claimed to be involved in chronic diseases. However, there are methods to check for HSV-1 
infection both in the periphery (HSV-1 specific IgG and IgM antibodies in plasma/sera) and in CSF 
(viral DNA and IgG/IgM specific antibodies) (Letenneur et al., 2008; Lovheim et al., 2014) and 
although these detections do not demonstrate that HSV-1 has reached the CNS, they allow studying 
the correlation between the infection state and neurodegeneration signals in patients. We have 
started the study of these markers in a small number of the individuals from our case/control 
cohort, whose samples were obtained, and these preliminary data are in line with the higher plasma 
IgM levels in patients reported by Letenneur et al., 2008. In the near future, we plan to extend the 
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analysis to a larger number of samples, mainly through collaborations in the context of the 
DEGESCO consortium.  
LAMP2 is known as one of the most abundant membrane proteins of the lysosome. 
Together with LAMP1 they constitute about half of all proteins of the lysosomal membrane, but 
little is known about their function (Endo et al., 2015; Eskelinen, 2006). Both are transmembrane 
proteins with a highly glycosylated luminal domain, a single transmembrane domain and a C-
terminal cytoplasmic tail. The molecular mass of LAMP2 is about 45 kDa, however with the 
glycosylation it raises up to 120 kDa (Carlsson et al., 1988; Mane et al., 1989). Alternative splicing 
of LAMP2 generates three isoforms, LAMP2A, -2B and -2C (Eskelinen et al., 2005). LAMP2A 
was identified as the receptor in the lysosomal membrane for substrate proteins of chaperone-
mediated autophagy (CMA) (Kaushik et al., 2012). Mutations in LAMP2 cause Danon disease, a X-
linked disorder characterized by hypertrophic cardiomyopathy and mental retardation (Endo et al., 
2015).  
To further understand their functions, researchers created LAMP1 and LAMP2 single or 
double deficient cell and animal models. Interestingly, LAMP2 single deficiency is more severe 
than LAMP1 single deficiency and replicates the phenotype observed in Danon disease patients in 
mice, like accumulation of autophagic vesicles in heart and skeletal muscle (Saftig et al., 2001). 
More recently, the work with KO mice revealed that LAMP2 deficiency leads to impaired 
phagosomal maturation in neutrophils causing periodontitis (Beertsen et al., 2008). Actually, this 
clinical outcome is caused by deficient fusion between phagosomes and lysosomes in affected 
animals. Given the severe LAMP2 KO phenotype, it is not surprising that double deficient animals 
present embryonic lethality at day 15.5. Absence of both LAMPs prevent the recruitment of late 
endosomal/lysosomal markers (Huynh et al., 2007). Another study indicated a role of LAMP2 in 
fusion events between autophagosomes and lysosomes. In this context, LAMP2 is required for 
syntaxin-17 (STX17) expression by the autophagosomes and subsequent interaction with VAMP8 
on lysosomes to mediate the fusion (Hubert et al., 2016). It is interesting to note that a role for 
LAMP2 in endo-lysosomal cholesterol transport has been suggested (Schneede et al., 2011). 
Probably, LAMP2 is required for cholesterol transport out late endosomes/lysosome and towards 
the ER for esterification. While MEFs deficient in LAMP2 showed accumulation of unesterified 
cholesterol in late endosomes/lysosomes, LAMP1-deficient MEFs did not (Eskelinen et al., 2004). 
A recent report demonstrated that LAMP2 is able to bind cholesterol directly and this capacity 
facilitates the cholesterol export from lysosomes (Li et al., 2016). 
LAMP2 is localized on the X chromosome, and mutations in LAMP2 consequently affect 
male and females in a gender-dependent manner. The facts that AD prevalence and clinical 
outcome are also gender-dependent (Genin et al., 2011; Lin et al., 2015) and HSV-1 infection 
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seems to affect more likely to females (Itzhaki, 2014) support the hypothesis of a possible 
implication of this gene in HSV-1-induced AD-like neurodegenerative events. In relation with 
pathogens, LAMP proteins have been shown to be necessary for microbicidal activity of 
phagosomes and LAMP double deficient fibroblasts were unable to digest Neisseria-containing 
phagosomes (Binker et al., 2007). Recent reports revealed LAMP2 as a target by viral proteins of 
the human immunodeficiency virus (HIV) and influenza A virus causing impairment of the 
lysosomal activity (Fields et al., 2015; Ju et al., 2015). 
In summary, our results show that LAMP2 expression is significantly upregulated in our 
cell model of infection and OS and LAMP2 gene is associated with a higher risk for AD. In 
addition, LAMP2 is able to modulate lysosomal function through different mechanisms including 
the transport of cholesterol and the fusion between autophagosomes and lysosomes. These data 
highlight the importance of LAMP2 for proper lysosomal function and supports our decision to 
study this candidate in relation to HSV-1-induced lysosomal dysfunction and neurodegeneration. 
To study whether LAMP2 is involved in the lysosomal dysfunction and AD-like 
neurodegenerative events induced by HSV-1 in our cell model, we generated LAMP2-deficient 
SK-N-MC cells. Although the commercial shRNAs used in this study were validated and should 
achieve a ~90% reduction in LAMP2 expression, we did not obtain any LAMP2-deficient cell lines 
with such efficient gene silencing (the strongest effect was a 67% reduction). Given the 90% 
reduction of LAMP2 protein levels in LAMP2-deficient N2a cells and the genetic deletion of 
LAMP2 in MEF cells derived from LAMP2 KO mice, we initiated the experiments in these two 
murine cell lines. As a first characterization step, the effect of LAMP2 deficiency on HSV-1 
infection was evaluated and showed that the lack of LAMP2 reduces HSV-1 infection efficiency. 
In LAMP2-deficient cells, less viral DNA and proteins were observed, as well as less infectious 
particles suggesting that LAMP2 might affect HSV-1 viral cycle. Further experiments need to be 
done in order to confirm this hypothesis. As mentioned before, LAMPs have been targeted by viral 
proteins of several viruses, like HIV and influenza A virus (Fields et al., 2015; Ju et al., 2015). To 
our knowledge, no interactions between HSV proteins and LAMPs have been reported. The fact 
that LAMP2 deficiency causes a less effective infection in our cells, however, might suggest 
otherwise. To check if LAMP2 could be interacting directly with HSV-1 proteins, co-
immunoprecipitation (Co-IP) experiments and in situ proximity ligation assays (PLAs) will be 
performed. Nevertheless, impairment of HSV-1 infection induced by LAMP2 deficiency could 
affect the neurodegenerative events induced by the virus.  
Cholesterol, as a major component of plasma membranes, is necessary for herpesvirus 
entry into the cells (Bender et al., 2003; Rahn et al., 2011). The absence of LAMP2 could cause 
cholesterol alterations and might reduce the virus ability to enter the cells. Beyond entry, HSV-1 
transcription and infectivity are also affected by cholesterol changes (Wudiri et al., 2014). 
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Pharmacological depletion of cholesterol by MβCD reduced plaque numbers in Vero cells (Wudiri 
et al., 2017). In line, LAMP2-deficient cells showed lower extracellular viral titer that might in part 
be caused by cholesterol alterations. To investigate this hypothesis, measurements of total and 
lysosomal cholesterol levels in LAMP2-deficient cells could provide further insight. Since the 
methods for cholesterol quantification and the partial purification of lysosomes are already standard 
protocol at our laboratory, these experiments will be initiated shortly. Additionally, levels and 
cellular distribution of cholesterol will be studied by microscopy experiments using filipin staining 
of the cells. The pharmacological modulation of cellular cholesterol levels will also be performed 
to see if the HSV-1-induced phenotype can be rescued by cholesterol depletion. 
Then, the impact of HSV-1 and OS on LAMP2 expression was also checked. In wt MEF 
and N2a cells, OS increased LAMP2 protein levels in all conditions tested and HSV-1 infection 
also induced an increment of LAMP2 levels in wt MEF cells, reproducing the results obtained in 
SK-N-MC cells. However, HSV-1 infection provoked a reduction of LAMP2 expression in a dose-
dependent manner in N2a cells. The HSV-1-induced decrease of LAMP2 levels in N2a cells is in 
contrast to the increase of lysosomal burden and LAMP2 levels in SK-N-MC cells provoked by the 
virus. Gene expression analysis also reported upregulation of LAMP2 by OS and HSV-1 in two 
independent methods (microarray and RT-qPCR). This discrepancy might be explained by the 
presence of cell-type specific effects.  
The neurodegenerative effects of HSV-1 infection in SK-N-MC cells are well known by 
our group. To see if these effects can be reproduced in MEF and N2a cells and evaluate if a 
differential response in LAMP2-deficient cells takes place, we started analysing Aβ, tau 
phosphorylation and LC3-II levels in both murine cell lines. Preliminary results confirm that the 
HSV-1-induced neurodegeneration was also observed. HSV-1 infection provoked increased levels 
of phosphorylated tau, accumulation of intracellular Aβ42 and the autophagic marker LC3-II, and 
an inhibition of the secretion of Aβ40 and Aβ42. Moreover, HSV-1 also diminished the activity of 
lysosomal hydrolases. Thus, these cell models fully recapitulate the pathologic markers found in 
HSV-1 infected SK-N-MC cells, and are appropriate to assess the role of LAMP2 in the HSV-1-
induced neurodegeneration. 
Preliminary results showed no significant differences in wt and LAMP2-deficient MEF and 
N2a cells suggesting that LAMP2 is not implicated in the generation of the AD-like 
neurodegenerative events. However, it is too soon to reach any conclusions. Some of the 
experiments lack replicates to reach statistical power and those might reveal subtle differences not 
detected so far. Also, the experiments will be performed under different infection conditions. 
Lower viral dose and extended incubation times might reveal alterations that are not present in the 
current approach. The fact that LAMP2 deficiency causes a lower production of infectious particles 
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indicates that, if LAMP2 is implicated in HSV-1-mediated neurodegeneration, changes might be 
observed at later time points when a full replication cycle has been completed. Furthermore, only 
LAMP2-deficient cells have been analysed so far. The opposite approach—LAMP2 
overexpression—might be useful to elucidate the role of LAMP2. Therefore, an additional SK-N-
MC cell line overexpressing LAMP2 will be generated. HSV-1 infection efficiency, lysosomal 
alterations, and AD-like neurodegeneration markers will be studied in this model of LAMP2 
overexpression.  
4. Generation of patient-specific iPSCs 
During the development of this thesis the generation of iPSCs was initiated. This model 
will be used to reproduce the results in a more physiological model. The discovery of defined 
factors that can reprogram somatic cells into iPSCs is a relatively recent development celebrating 
its 10 years anniversary. In 2006, Yamanaka’s group published the combination of four factors 
sufficient for reprogramming mouse fibroblasts—OCT3/4, SOX2, cMYC, and KLF4 (Takahashi et 
al., 2006)—and only one year later they proved the concept valuable as well for human fibroblasts 
(Takahashi et al., 2007). The cocktail of these four factors is commonly known as the Yamanaka 
factors. The great potential of this method for modelling and investigating human disease, as well 
as drug screening was quickly noted. To date, hundreds of established cell lines from patients with 
familial and sporadic AD, Parkinson’s disease, and many other diseases were published 
(summarised in Mungenast et al., 2016).  
We started the generation of two individual iPSC lines from each subject—one SAD 
patient and one age-matched control. After the successful generation of fibroblasts from skin 
biopsies, those were reprogrammed by delivery of the Yamanaka factors with Sendai virus (SeV) 
vectors. Initially, the stepwise morphological changes were observed as expected and colonies 
emerged giving rise to individual iPSC lines. Before their characterization, each line was passaged 
more than 10 times to make sure the SeV vectors were eliminated from the cells. In this period of 
time, the cell lines derived from the control individual showed differentiated cells inside the 
colonies indicating a not fully reprogrammed state. The exogenous expression of the Yamanaka 
factors might have caused the initial iPSC-like phenotype. However, cell lines were positive for 
TRA1-60, a marker for pluripotency, which was not one of the initial transduced factors indicating 
that some of the cellular endogenous battery of pluripotent genes was temporally stimulated. The 
appearance of only partial reprogrammed colonies is quite common during the establishment of 
individual human iPSC lines. Literature states that age and source of the cell type strongly 
influence reprogrammability and that fibroblasts show a high background of non-iPSC colonies 
(Lowry et al., 2008). The reprogramming efficiency of the used method was estimated to vary 
between 0.01 and 1%. However, extraction of a skin biopsy is a non-invasive procedure for the 
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donor and was considered as the only feasible option within this thesis project. Further, many other 
factors are important for reprogramming efficiency and successful growing, like delivery method 
of the defined factors, passage skills, culture conditions, quality of feeder cells, etc. (discussed in 
Maherali et al., 2008). Since reprogramming efficiency in general is still very low, a new concept 
has evolved avoiding the pluripotent state and directly converting somatic cells into another cell 
lineage by chemical factors. This method is called direct reprogramming. In 2012 researchers 
successfully generated neuronal-like cells directly from human fibroblasts (Ladewig et al., 2012). 
Recently, two studies reported the direct conversion of fibroblasts into neurons obtained from AD 
(Hu et al., 2015) or Huntington’s disease (Liu et al., 2014) patients. Direct reprogramming as 
alternative method should be taken into consideration.  
However, the two patient-derived cell lines under characterization confirmed their 
pluripotent state in the experiments performed so far. Both—immunofluorescence and RT-qPCR—
showed the expression of pluripotent markers. Further, the mRNA levels of markers characteristic 
for differentiation were negative confirming the pluripotency of these cell lines. Several tests still 
have to be performed before characterization is complete, but so far it seems like the generated 
iPSC lines are adequate for further investigations. 
These cell lines will be used to characterize their response to HSV-1 infection and OS. We 
will evaluate if there are differences in the lysosomal alterations and AD-like neurodegenerative 
events induced by HSV-1 and OS between control- and patient-derived cells. These experiments 
will be performed either with iPSCs directly or after their differentiation into neurons. 
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The results obtained in the present thesis permit the following conclusions to be drawn: 
 
1. Oxidative stress modulates the expression of a set of genes in a human neuronal cell line 
infected with HSV-1 (as a model of sporadic AD) or harbouring the APP Swedish 
mutation (as a model of familial AD). Functional enrichment analysis of these genes 
identified the impairment of the lysosomal pathway as a putative common pathogenic 
mechanism for sporadic and familial Alzheimer’s disease. 
2. The functional analysis of the lysosomal pathway in the sporadic AD cell model showed 
that several aspects of the lysosomal system were severely altered. HSV-1 and oxidative 
stress increased lysosomal burden and decreased the degradative activity of the lysosomal 
system. These results suggest that the lysosomal dysfunction observed could underlay the 
AD-like neurodegeneration induced by HSV-1 and oxidative stress. 
3. The intracellular accumulation of cholesterol, likely in endo-lysosomal compartments, 
induced by HSV-1 and oxidative stress indicates that alterations of cholesterol 
homeostasis might be one of the mechanisms involved in the lysosomal dysfunction 
induced by HSV-1 and oxidative stress. 
4. Genetic association studies identified common variants in the lysosomal-associated 
membrane protein 2 (LAMP2) gene as putative risk factors for sporadic AD pointing to 
LAMP2 as a suitable candidate to participate in the lysosomal alterations and the 
neurodegeneration events induced by HSV-1 and oxidative stress. 
5. HSV-1 induced the appearance of the main AD-like neurodegenerative markers in 
wildtype and LAMP2-deficient murine embryonic fibroblasts and murine neuroblastoma 
N2a cells, including the phosphorylation of tau and the accumulation of intracellular Aβ. 
In addition, LAMP2 deficiency did not affect the neurodegenerative events induced by 
HSV-1, at least during the first infection viral cycle, but strongly reduced the efficiency of 
the infection.  
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El trabajo experimental realizado en esta tesis ha permitido obtener las siguientes conclusiones: 
 
1. El estrés oxidativo modula la expresión de un conjunto de genes en células neuronales 
humanas infectadas con HSV-1 (como modelo de la EA esporádica) y en células 
portadoras de APP con la mutación “sueca” (como modelo de la EA familiar). El análisis 
bioinformático de enriquecimiento funcional de estos genes identificó la vía lisosomal 
como un posible mecanismo patogénico común en las formas familiar y esporádica de la 
enfermedad. 
2. El estudio funcional de la vía lisosomal en el modelo celular de EA esporádica mostró que 
varios aspectos del sistema lisosomal están fuertemente alterados. La infección por HSV-1 
y el estrés oxidativo aumentan los niveles lisosomales pero disminuyen la actividad 
degradativa de los lisosomas. Estos resultados sugieren que la disfunción lisosomal podría 
estar implicada en la neurodegeneración inducida por HSV-1 y el estrés oxidativo. 
3. La acumulación intracelular de colesterol, probablemente en compartimentos endo-
lisosomales, inducida por HSV-1 y el estrés oxidativo indica que la alteración de la 
homeostasis del colesterol podría constituir uno de los mecanismos implicados en la 
disfunción lisosomal inducida por estos dos factores. 
4. Estudios de asociación genética señalan a variantes comunes en el gen de la proteína de 
membrana asociada al lisosoma 2 (LAMP2) como un posible factor de riesgo para la EA 
esporádica. Estos datos sugieren que LAMP2 podría ser un candidato idóneo para mediar 
la disfunción lisosomal y la neurodegeneración inducida por HSV-1 y el estrés oxidativo.  
5. HSV-1 induce la aparición de los principales marcadores de neurodegeneración 
característicos del alzhéimer, incluyendo la fosforilación de tau y la acumulación 
intracelular de Aβ, en fibroblastos embrionarios de ratón y células de neuroblastoma 
murino N2a control y deficientes en LAMP2. Además, la deficiencia de LAMP2 no afecta 
a los eventos de neurodegeneración inducidos por HSV-1, al menos durante el primer 
ciclo de replicación viral, aunque sí reduce significativamente la eficiencia de infección.  
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